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CHAPTER ONE
INTRODUCTION
1.1 Background 
The term malaria  originated from  Medieval Italian:  mala aria meaning "bad air"; and the 
disease was formerly called ague or marsh fever due to its association with swamps. Malaria 
is the most prevalent tropical disease in the world today. It has infected humans for over fifty 
thousand years, and may have been a human pathogen for the entire history of our species. In 
the  tropical  and  subtropical  regions,  during  the  first  half  of  the  twentieth  century,  malaria 
affected every walk of life so much so that one of the major problems in development of economy 
was the problem of malaria (Sacks and Malaney, 2002).
Malaria is  a  vector-borne  infectious  disease caused  by  protozoan parasites of  the  genus 
Plasmodium and is presently endemic in a broad band around the equator, in areas of the 
Americas, many parts of Asia and much of Africa, however, it is in sub-Saharan Africa that 
85– 90% of malaria fatalities occur (Hay et al., 2004). It is estimated that up to 124 million 
people in Africa live in areas at risk of seasonal epidemic malaria, and many more in areas 
outside Africa where transmission is  less intense (Hay and Snow, 2006).  Each year,  it  is 
estimated to cause disease in approximately 650 million people and kills between one and 
three million, mostly young children in  Sub-Saharan Africa (Hay  et al., 2004). It is also a 
cause of poverty and a major hindrance to economic development (Sachs and Malaney, 2002). 
The economic impact includes costs of health care, working days lost due to sickness, days 
lost in education, decreased productivity due to brain damage from cerebral malaria, and loss 
of investment and tourism (WHO, 2001). Moreover, it remains one of the leading causes of 
death in Sub-Sahara regions where Human Immunodeficient Virus (HIV) infection is endemic 
(Korenromp et al., 2005). 
Malaria causes about 500 million clinical cases each year (10% of the world population), and 
more than 1 million,  mostly children, die as a result of this disease (Breman, 2001). This 
translates  into a death from malaria  every 30 seconds,  rendering it  an eminent  disease in 
tropical  countries  and  ranking  it  the  third  killer  among  communicable  diseases  behind 
HIV/AIDS  and  tuberculosis  (Greenwood  and  Mutabingwa,  2002).  Malaria  has  been  a 
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common disease and it  continues  to  be one  of  the most  widely spread health  hazards  in 
tropical and subtropical regions. More than half of the world's population lives in the areas 
where they remain at risk of malarial infection.  The vast majority of cases occur in children 
under the age of five years and pregnant women (Greenwood et al., 2005; Adefioye  et. al., 
2007).
Despite efforts to reduce transmission and increase treatment, there has been little change in 
the areas that are at risk of this disease since 1992 (Hay et al., 2004). Indeed, if the prevalence 
of malaria stays on its present upwards course, death rate could double in the next twenty 
years (Sacks and Malaney, 2002). Precise statistics of morbidity and mortality are unknown 
because many cases occur in rural areas where people do not have access to hospitals or the 
means to afford health care. Consequently, the majority of cases of malaria are undocumented 
(Breman,  2001;  Desai  et  al.,  2007).  The  main  cause  of  the  worsened  malaria  situation 
recorded in recent years has been the spread of drug-resistant parasites, which has led to rising 
malaria-associated  mortality,  even though overall  child  mortality  has  fallen  (Snow  et  al.,  
2001).
Until recently, there has been a reliance on the cheap antimalarial drugs like Chloroquine and 
Sulphadoxine-Pyrimethamine. In 2001, the World Health Organization (WHO) recommended 
Artemisinin combination Therapies (ACTs) as the first line of treatment for uncomplicated 
malaria  (WHO,  2001).  The  ACTs  which  include  Artemether-lumefantrine  (AL)  and 
Amodiaquine (AQ) plus artesunate (AS) have been adopted for treatment of  P. falciparum 
malaria  in  many  African  countries.  To  protect  drugs  from resistance,  there  is  now clear 
evidence that combining them can improve their  efficacy without increasing their  toxicity 
(Olliaro  and  Taylor,  2002)  and  with  the  development  of  highly  effective  artemisinin 
derivatives, there is renewed hope for the treatment of malaria in the form of Artemisinin-
Based Combination therapy (ACT). 
The  resistance  of  human  malaria  parasites  to  antimalarial  compounds  has  become  of 
considerable  concern,  particularly  in  view  of  the  fast  speed  of  emergence  of  resistant 
parasites,  the  fast  spread  of  resistant  parasites,  and  the  shortage  of  novel  classes  of 
antimalarial drugs. Antimalarial drug resistance has emerged as one of the greatest challenges 
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facing malaria control today and has also been implicated in the spread of malaria to new 
areas and re-emergence of malaria in areas where the disease had been eradicated (Bloland, 
2001). Drug resistance has also played a significant role in the occurrence and severity of 
epidemics in some parts of the world. Population movement has introduced resistant parasites 
to  areas  previously  free  of  drug  resistance.  The  emergence  and  spread  of  P.  falciparum 
resistance to antimalarial drugs is now one of the greatest challenges facing the global effort 
to  control  malaria  in  Africa  (WHO,  2003). Moreover,  in  recent  years  the  situation  has 
worsened  due  to  malaria  parasite  becoming  resistant  to  several  antimalarial  drugs.  This 
resistance concerns numerous drugs, but is thought to be most serious with Chloroquine, the 
cheapest and most widely used drug to treat malaria (Sucharit  et al., 1977). There have also 
been reports of resistance against new drugs such as Mefloquine-Lumefantrine (Riamet®), 
Mefloquine,  Atovaquone-proguanil (Malarone®)  and  Cotrifazid  Doxycycline and 
Mefloquine (Lariam®) (Mccollum et al., Hyde, 2002; 2006; Noedl et al., 2008).   
Several medicinal plants have also been used locally to treat malaria infection. Some of such 
plants  are  Enantia  chloranta,  Nauclea  natifolia,  Salacia  nitida  (Ogbonna  et  al.,  2008), 
Acalypha fruticosa, Azadirachta indica, Cissus rotundifolia, Echium rauwalfii, Dendrosicyos  
socotrana and  Boswellia  elongate  (Merlin,  2004; Clarkson  et  al.,  2004;  Alshwash  et  al.,  
2007), Cymbopogon giganteus and Morinda lucida (Awe and Makinde, 1997; Azas  et al., 
2002).The use of these local herbs for the treatment of malaria has helped to reduce mortality 
and morbidity rates especially in the rural areas of the developing world where antimalarial 
drugs are not readily available. One way to prevent drug resistance of pathogenic species is by 
using new compounds that are not based on existing synthetic antimicrobial agents (Azas et  
al., 2002). Traditional healers claim that some medicinal plants are more efficient to treat 
infectious diseases than synthetic antibiotics. Medicinal plants might represent an alternative 
treatment in non-severe cases of infectious diseases. They can also be a possible source for 
new potent antibiotics to which pathogenenic strains are not resistant (Elujoba  et al., 2005; 
Ogbonnaa et al., 2008).  
Malaria  remains  uncontrolled  and  requires  newer  drugs  and  vaccines.  Untill  the  malaria 
vaccine and newer class of antimalarial drugs become available, the existing drugs need to be 
used cautiously. This is because the irrational use of antimalarial drugs can cause the drug 
resistant malaria. Effective usage of existing antimalarial drugs for malaria control strategies 
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requires continuous input of the drug resistance pattern in the field. Resistance to antimalarial 
drugs can be assessed in vivo and also in vitro by parasite susceptibility assays or by the use 
of  molecular  techniques  including  Polymerase  Chain  Reaction  (PCR)  methods  to  detect 
genetic markers. In vivo tests are traditionally the “gold standard” method for detecting drug 
resistance  (WHO,  1996).   This  involves  the  assessment  of  clinical  and  parasitological 
outcomes of treatment over a certain period following the start of treatment, to check for the 
re-appearance of parasites in the blood.  In vitro assays are based on the inhibition of the 
growth and development of malaria parasites by different concentrations of a given drug, in 
relation  to  drug-free  controls  (WHO,  1996).  The  WHO  in  vitro micro-test  is  based  on 
counting the parasites developing into schizonts,  while the isotopic micro-test is based on 
measurement of the quantity of radio-labeled hypoxanthine, a DNA precursor, incorporated 
into  the  parasites  (Childs et  al.,  1988).  Molecular  methods  are  now  being  used  for  the 
detection of malaria infection in both clinical and research laboratories using PCR method 
(Mens et al., 2006). 
PCR is the most important new scientific technology to come along in the last hundred years 
(Beck, 1999; de Monbrison  et al., 2003).  This technique is more accurate than microscopy 
and its value lies in its sensitivity with the ability to detect ≤5 parasites/µl of blood with 100% 
sensitivity and equal specificity. PCR  methods are particularly useful for studies on strain 
variation, mutations and studies of parasite genes involved in drug resistance. Rapid real-time 
assays  (Real  time  PCR,  Quantitative  Nucleic  Acid  Sequence  Based  Amplification,  QT-
NASBA) based on the polymerase chain reaction are emerging as high-throughput genotyping 
platforms (Ojurongbe et al., 2007).  Molecular studies using various markers can provide the 
advance information on the emergence of drug resistance pattern in the field and such can be 
used to design malaria control strategies. Using molecular studies, point mutations on the P. 
falciparum Chloroquine  Resistant  Transporter  (PfCRT)  and  P.  falciparum Multi-drug 
Resistant1 (PfMDR1) genes have been reported to play an additional role for the chloroquine 
resistance in  P. falciparum isolates while dhfr and dhps were associated with resistance to 
sulfadoxine-pyrimethamine (Ittarat  et al., 1994; Adagu and Warhurst, 1999).
 
A major breakthrough in the search for the genetic basis of CQR in  P. falciparum  was the 
identification of PfCRT gene, which encodes a putative transporter or channel protein (Fidock 
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et  al.,  2000).  A  K76T  change  on  the  PfCRT  gene  appears  necessary  for  the  resistance 
phenotype, and is the most reliable molecular marker of resistance among the various fifteen 
polymorphic  amino  acid  positions  in  PfCRT gene  associated  with  CQR in  field  isolates 
(Djimde et al., 2001; Plowe, 2003; Ojurongbe et al., 2007). PfMDR1, is a homologue of the 
mammalian multiple drug resistance gene encoding a P-glycoprotein on the chromosome 5 of 
the  P.  falciparum.  Several  field  studies  indicated  the  positive  association  between  the 
asparagine to tyrosine change at position 86 (N86Y) and the chloroquine resistance both  in 
vitro (Adagu and Warhurst, 1999; Basco and Ringwald, 2001; Pickard  et al., 2003) and  in  
vivo (Ringwald and Basco, 1999; Basco and Ringwald, 2001; Dorsey et al., 2001). However, 
other studies have cast doubts on this association (Pillai et al., 2001; Ojurongbe et al., 2007).
In  vitro  resistance  of  P.  falciparum  to  pyrimethamine  and  to  chlorcycloguanil  is  due  to 
specific point mutations in P. falciparum Dihydrofolate reductase (DHFR), which is encoded 
by a bi-functional gene (dhfr-ts) also encoding thymidylate synthase (Kublin  et al.,  2002; 
Marks  et  al.,  2005).  A single point  mutation  causing a  Serine (Ser)  to Asparagine (Asn) 
change  at  codon  108  causes  pyrimethamine  resistance  with  only  a  moderate  loss  of 
susceptibility to chlorcycloguanil. The addition of Asn to Isoleucine (Ile) at position 51 and/or 
Cysteine (Cys) to  Arginine (Arg)  at  position 59  confers  higher  levels  of  pyrimethamine 
resistance. Ile to Leucine (Leu) at position 164, when combined with Asn108 and Ile51 and/or 
Arg59,  confers  high-level  resistance  to  both drugs.  Point  mutations  in  the  gene encoding 
DHPS have similarly been associated with in vitro resistance to the sulfa drugs and sulfones. 
Mutations associated with decreased susceptibility to sulfas include Ser to Alanine (Ala) at 
position 436, Ala to Glycine (Gly) at position 437, Ala to Gly at position 581, and Ser to 
Phenylalanine (Phe) at position 436 coupled with Ala to Threonine (Thr)/Ser at position 613 
(Plowe  et al.,  1998; Marks  et al.,  2005; McCollum  et al.,  2006). Both DHFR and DHPS 
mutations occurs in a progressive, step-wise fashion, with higher levels of in vitro resistance 
occurring in the presence of multiple mutations (Plowe et al., 1998; Marks et al., 2005)
In the absence of effective and practical preventive measures, the only current options for 
reducing the morbidity and mortality of malaria especially in Africa are chemoprophylaxis 
and chemotherapy.  For  this  reason,  the  increasing  prevalence  of  strains  of  P.  falciparum 
resistant to antimalarial drugs poses a serious problem for the control of malaria. 
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In  Nigeria,  malaria  accounts for high infant and childhood mortality  and it  imposes great 
burden on the country in terms of pains and trauma suffered by its victims as well as loss in 
outputs and cost of treatments.  In addition to the use of orthodox medicine for treatment, 
personal communication has shown that malaria is often treated in Nigeria with local herbs 
and the services of spiritualists/traditional priests.  Similarly,  common prevention measures 
include use of drugs (prophylaxis), insecticides (coils and sprays), ordinary mosquito nets, 
Insecticide-Treated Nets (ITNs) and window/door nets (Ojo, 2005).   
1.2 Justification/Rationale of the Study
Emerging  drug-resistant  P.  falciparum strains  are  making  malaria  a  resurging  infectious 
disease. Moreover, in recent years the situation has worsened in many ways mainly due to the 
malaria parasite becoming resistant to almost all available antimalarial drugs.
Newer drug therapies,  unfortunately,  have not eluded drug resistant  strains of the malaria 
parasite  as  there  have  also  been  case  reports  of  resistance  against  new  drugs  such  as 
Atovaquone-proguanil, (malarone®) cotrifazid, doxycycline, mefloquine (Lariam®).
Effective usage of existing antimalarial drugs requires continuous input of the drug resistance 
pattern in the field. In-Vitro drug sensitivity assays  provide information on the quantitative 
drug response of  P. falciparum;  they are therefore important tools for monitoring the drug 
response of  P. falciparum  and they provide background information  for development  and 
evaluation of drug policies. 
In addition,  in-vitro drug sensitivity assays serve as epidemiological tools to assess baseline 
sensitivity which can be an indicator of future therapeutic failure. They can also guide on the 
partner drug in Artemisinin Combination Therapies (ACTs).
This study was therefore designed to assess the in vitro sensitivity pattern and the molecular 
characteristics of P. falciparum that are likely to influence the observed resistance to these 
new antimalarial drugs; and also to test the efficacy of some selected Nigerian herbs used as 
local antimalarial drugs. This will contribute to the development of novel antimalarial drugs 
thus circumventing the resistance potentials of this parasite. 
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1.3 Objectives of the Study 
The objectives of this study are to:
1. establish  the  incidence  of   malaria  (Plasmodium infection)  in  Ogun  State, 
Southwestern Nigeria
2. assess the resistance patterns of P. falciparum to the current antimalarial drugs
3. determine the prevalence of  molecular markers of resistance to different classes of 
antimalarial drugs 
4. establish  the  factors  that  may  contribute  to  the  development  of  antimalarial  drug 
resistance in Southwestern Nigeria.
5. determine the efficacy of some Nigerian herbs used as local antimalarial drugs/drinks 
in vitro.
1.4 Scientific Hypotheses
1. There is a wide spread of multidrug drug resistant P. falciparum
2. In vitro susceptibility testing can provide information on drug resistance pattern of P.
falciparum to the new drugs that are currently in use.
3.  Molecular studies using various markers can provide advance information on the
 emergence of drug resistance pattern in the field. 
4. The misuse/abuse of antimalarial drugs results in fast development of resistance of P. 
falciparum to antimalarial drugs.
5. There is efficacy in the local herbs used as antimalarial drugs 
CHAPTER TWO
LITERATURE REVIEW
 2.1. Disease Incidence and Trends
Malaria remains an important public health concern in countries where transmission occurs 
regularly, as well as in areas where transmission has been largely controlled or eliminated. In 
particular, young children, pregnant women, and non-immune visitors to malarious areas are 
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at greatest risk of severe or fatal illness. Ninety percent of the global burden of malaria occurs 
in Africa, south of Sahara and in spite of the considerable efforts in the campaign against 
malaria, the number of cases and deaths associated with the disease remain almost unvaried 
(WHO,  2001).  Reasons  for  this  include  the  emergence  of  parasite  resistance  to  drugs, 
resistance of their vectors to insecticides, demographic growth with ensuing deterioration of 
living  and  infrastructure  standards  in  endemic  areas,  environmental  degradation,  armed 
conflicts  leading to large movement of refugees,  uncontrolled movement through endemic 
areas and natural disasters (Bourdy et al., 2008) 
2.1.1. Geographical Distribution and Populations at Risk
Malaria occurs in over 90 countries worldwide (Bloland, 2001). WHO estimated that 36% of 
the global population live in areas where there is risk of malaria transmission, 7% reside in 
areas where malaria has never been under meaningful control and 29% live in areas where 
malaria was once transmitted at low levels or not at all, but where significant transmission has 
been re-established (WHO, 1996a). The development and spread of drug-resistant strains of 
malaria parasites has been identified as a key factor in this resurgence (Bloland, 2001) and is 
one of the greatest challenges to malaria control today. Malaria transmission occurs primarily 
in tropical and subtropical regions in sub-Saharan Africa,  Central and South America, the 
Caribbean island of Hispaniola, the Middle East, the Indian subcontinent, South-East Asia, 
and  Oceania  (Hay  and  Snow,  2006).  In  areas  where  malaria  occurs,  however,  there  is 
considerable variation in the intensity of transmission and risk of malaria infection. Highlands 
(greater than 1500 m) and arid areas with less than 1000 mm rainfall per annum typically 
have  less  malaria,  although  they  are  also  prone  to  epidemic  malaria  when  parasitaemic 
individuals provide a source of infection and climate conditions are favourable to mosquito 
development (WHO 1996). Although urban areas have typically been at lower risk, explosive, 
unplanned  population  growth  has  contributed  to  the  growing  problem  of  urban  malaria 
transmission (Knudsen and Slooff, 1992).
Each year an estimated 300 to 650 million clinical cases of malaria occur, making it one of 
the most common infectious diseases worldwide (Hay et al., 2004). Malaria can be, in certain 
epidemiological  circumstances,  a  devastating  disease  with  high  morbidity  and  mortality, 
demanding a rapid, comprehensive response. In other settings, it can be a more pernicious 
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public health threat.  In many malarious areas of the world, especially sub-Saharan Africa, 
malaria is ranked among the most frequent causes of morbidity and mortality among children 
(Greenwood et al., 2005). It has been estimated that more than 90% of the 1.5 to 3.0 million 
deaths attributed to malaria each year occur in African children (Hay  et al.,  2004). Other 
estimates  based  on a  more  rigorous  attempt  to  calculate  the  burden of  disease  in  Africa 
support  this  level  of  mortality  (Snow  et  al., 1999).  In  addition  to  its  burden in  terms of 
morbidity and mortality, the economic effects of malaria infection can be tremendous. These 
include  direct  costs  for  treatment  and  prevention,  as  well  as  indirect  costs  such  as  lost 
productivity  from morbidity  and mortality;  time spent seeking treatment,  and diversion of 
household resources (Sachs and Malaney, 2002).  The annual economic burden of malaria 
infection in 1995 was estimated at  US$ 0.8 billion,  for Africa alone (Bloland 2001). This 
heavy toll can hinder economic and community development activities throughout the region. 
More than ever before malaria is both a disease of poverty and a cause of poverty (Bourdy et  
al., 2008).
Nigeria is known for high prevalence of malaria and it is a leading cause of morbidity and 
mortality in the country (Ademowo et al., 2006). Available records show that at least 50 per 
cent of the population of Nigeria suffers from at least one episode of malaria each year and 
that  malaria  accounts  for  over  45% of  all  out  patient  visits.  It  was  reported  that  malaria 
prevalence (notified cases) in year 2000 was about 2.4 million (Sowunmi et al., 2004). The 
disease accounts for 25 per cent of infant mortality and 30 per cent of childhood mortality in 
Nigeria.  Therefore,  it  imposes  great  burden on the  country in  terms of  pains  and trauma 
suffered by its victims as well as loss in outputs and cost of treatments (Ogungbamigbe et al., 
2005).  
2.2. Causative Agents
Malaria is caused by intracellular protozoan parasites of the genus Plasmodium. The parasite 
belongs  to  Kingdom  Protista,  Phylum  Apicomplexa,  Class  Aconoidasida,  Order 
Haemosporida, Family Plasmodiidae, Genus  Plasmodium and Species  falciparum The most 
serious forms of the disease are caused by P. falciparum and P.  malariae, but other related 
species  (P.  ovale,  P.  vivax)  can  also  infect  humans.  This  group  of  human-pathogenic 
Plasmodium species is usually referred to as  malaria parasites  (Trampuz  et al., 2003).  P. 
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falciparum,  P.  vivax,  P.  ovale,  and  P.  malariae  differ  in  geographical  distribution, 
microscopic  appearance,  clinical  features,  periodicity  of  infection,  potential  for  severe 
disease, ability to cause relapses, and potential for development of resistance to antimalarial 
drugs.  To date,  drug resistance has only been documented in  two of the four species,  P. 
falciparum and P. vivax (Bloland, 2001). 
2.3 Transmission and Biology of P. falciparum
Malaria can be transmitted by several species of female anopheline mosquitoes that differ in 
behavior (Greenwood et al., 2005). There are about 460 species of the Anopheles mosquito, 
but only 68 transmit malaria.  Anopheles gambiae, found in Africa is one of the best malaria 
vectors  since  it  is  long-lived,  prefers  feeding  on humans,  and  lives  in  areas  near  human 
habitation (Cowman, 2006). 
Prior to transmission,  P. falciparum resides within the salivary gland of the  mosquito. The 
parasite is in its sporozoite stage at this point. As the mosquito takes its blood meal, it injects 
a small amount of saliva into the skin wound. The saliva contains antihemostatic and anti-
inflammatory enzymes that disrupt the clotting process and inhibit the pain reaction (Bruce 
Chwatt,  1985).  Typically,  each infected  bite  contains  5-200  sporozoites which proceed to 
infect  the  human  (Gilles  et  al.,  1993).  Once  in  the  human  bloodstream,  the  sporozoites 
circulate for a few minutes before infecting liver cells. 
Liver Stage
After  circulating  in  the  bloodstream,  the  P.  falciparum sporozoites enter  hepatocytes to 
initiate  the  exoerythrocytic  stage.  At  this  point,  the  parasite  loses  its  apical  complex and 
surface coat, and transforms into a  trophozoite. Within the parasitophorous vacuole of the 
hepatocyte,  P.  falciparum undergoes  schizogonic  development.  In  this  stage,  the  nucleus 
divides multiple times with a concomitant increase in cell size, but without cell segmentation. 
This exoerythrocytic schizogony stage of P. falciparum has a minimum duration of roughly 
5.5 days. After segmentation, the parasite cells are differentiated into  merozoites (Miller  et  
al., 1994). After maturation, the merozoites are released from the hepatocytes and enter the 
erythrocytic portion of their life-cycle. The released merozoites do not reinfect hepatocytes.
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 Erythrocytic Stage
After release from the hepatocytes, the  merozoites enter the bloodstream prior to infecting 
red blood cells. At this point, the merozoites are roughly 1.5μm in length and 1 μm in 
diameter, and use the apicomplexan invasion organelles (apical complex, pellicle and 
surface coat) to recognize and enter the host erythrocyte (Bruce Chwatt  1985).The 
parasite first binds to the erythrocyte in a random orientation. It then reorients such 
that the apical complex is in proximity to the erythrocyte membrane. A tight junction 
is formed between the parasite and erythrocyte. As it enters the red blood cell,  the 
parasite  forms  a  parasitophorous  vesicle,  to  allow  for  its  development  inside  the 
erythrocyte (Gilles et al., 1993). 
After  invading  the  erythrocyte,  the  parasite  loses  its  specific  invasion  organelles  (apical 
complex and  surface  coat)  and  differentiates  into  a  round  trophozoite located  within  a 
parasitophorous vacuole in the red blood cell cytoplasm. The young  trophozoite (or "ring" 
stage,  because  of  its  morphology  on  stained  blood  films)  grows  substantially  before 
undergoing schizogonic division (Arora and Arora, 2005). The growing parasite replicates its 
DNA multiple times without cellular segmentation to form a schizont. These schizonts then 
undergo cellular segmentation and differentiation to form roughly 16-18 merozoite cells in the 
erythrocyte (Gills et al., 1993). The merozoites burst from the red blood cell, and proceed to 
infect other erythrocytes. The parasite then stays in the bloodstream for roughly 60 seconds 
before  invading another  erythrocyte.  This  infection  cycle  occurs  in  a  highly  synchronous 
fashion,  with  roughly  all  of  the  parasites  throughout  the  blood  in  the  same  stage  of 
development.  This  precise  clocking  mechanism  has  been  shown  to  be  dependent  on  the 
human host's  own  circadian  rhythm.  Specifically,  human body temperature  changes,  as  a 
result of the circadian rhythm, seem to play a role in the development of P. falciparum within 
the erythrocytic stage (Bruce Chwatt, 1985).
Within  the  red  blood  cell,  the  parasite  metabolism  depends  greatly  on  the  digestion  of 
hemoglobin. Infected erythrocytes are often sequestered in various human tissues or organs, 
such as the heart,  liver and brain. This is caused by parasite-derived cell  surface proteins 
being present on the red blood cell membrane and it is these proteins that bind to receptors on 
human cells. Sequestration in the brain causes cerebral malaria,  a very severe form of the 
disease,  which  increases  the  victim's  likelihood  of  death.  The  parasite  can  also  alter  the 
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morphology of the red blood cell, causing knobs on the erythrocyte membrane (Miller et al., 
1994).
Gametocyte Differentiation
During the erythrocytic stage, some merozoites develop into male and female gametocytes in 
a process called gametocytogenesis (Billker et al., 1998). These gametocytes take roughly 8-
10 days  to  reach  full  maturity  and remain  within  the  erythrocytes  until  taken  up by the 
mosquito host.
Mosquito Stage
The gametocytes of P. falciparum are taken up by the female Anopheles mosquito as it takes 
its blood meal from an infected human. Upon being taken up by the mosquito, they leave the 
erythrocyte shell and differentiate into gametes. The female gamete maturation process entails 
slight morphological changes, as it becomes enlarged and spherical. On the other hand, the 
male gamete maturation involves significant morphological development. The male gamete's 
DNA divides three times to form eight nuclei  and concurrently,  eight  flagella are formed. 
Each  flagella pairs  with a nucleus to form a microgamete,  which then separates from the 
parasite  cell  in a  process referred  to  as  exflagellation (Gilles  et  al., 1993).Gametogenesis 
(formation of gametes) has been shown to be caused by: 1) a sudden drop in temperature upon 
leaving the human host, 2) a rise in pH within the mosquito, and 3) xanthurenic acid within 
the mosquito (Billker et al., 1998). 
Fertilization of the female gamete by the male gamete occurs rapidly after gametogenesis. 
The fertilization event produces a  zygote. The  zygote then develops into an  ookinete. The 
zygote and ookinete are the only diploid stages of P. falciparum. The diploid ookinete is an 
invasive form of P. falciparum within the mosquito. It traverses the peritrophic membrane of 
the  mosquito midgut and crosses the midgut epithelium. Once through the epithelium, the 
ookinete enters the basil  lamina,  and forms an  oocyst.  During the  ookinete stage,  genetic 
recombination can occur. This takes place if the ookinete was formed from male and female 
gametes  derived  from different  populations.  This  can  occur  if  the  human  host  contained 
multiple populations of the parasite, or if the  mosquito fed on multiple infected individuals 
within a short time-frame (Bruce Chwatt, 1985).
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Over the period of 1-3 weeks, the oocyst grows to a size of tens to hundreds of micrometres. 
During  this  time,  multiple  nuclear  divisions  occur.  After  maturation,  it  divides  to  form 
multiple  haploid  sporozoites  in  a  process  referred  to  as  sporogony.  Immature  sporozoites 
break through the oocyst wall into the haemolymph, then migrate to the salivary glands and 
complete their differentiation. Once mature, the sporozoites can proceed to infect a human 
host during a subsequent mosquito bite (Gilles et al., 1993).
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Fig 2.1 Life cycle of Plasmodium Species.
(Bruce Chwatt, 1985)
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2.4. Symptoms
Malaria is a complex disease that varies widely in epidemiology and clinical manifestation in 
different parts of the world. This variability is due to factors such as the species of malaria 
parasites  that  occur  in  a  given  area,  their  susceptibility  to  commonly  used  or  available 
antimalarial  drugs,  the  distribution  and efficiency  of  mosquito  vectors,  climate  and other 
environmental conditions and the behavior and level of acquired immunity of the exposed 
human  populations  (Greenwood  et  al.,  1991;  Mockenhaupt  et  al., 2000).  The  parasites 
multiply within the red blood cells, causing symptoms that include symptoms of anemia (light 
headedness, shortness of breath, tachycardia etc.), as well as other general symptoms such as 
fever,  chills,  nausea,  flu-like  illness,  arthralgia (joint  pain),  vomiting,  anemia caused  by 
hemolysis,  hemoglobinuria,  and  convulsions and in  severe  cases,  coma and death  (WHO 
1991). 
The classical symptom of malaria is cyclical occurrence of sudden coldness followed by rigor 
and then fever and sweating lasting four to six hours, occurring every two days in P. vivax and 
P.  ovale infections,  while  it  occurs  every  three  days  in  P.  malariae  (Boivin,  2002).  P. 
falciparum can  have  recurrent  fever  every  36-48 hours  or  a  less  pronounced and almost 
continuous fever (Trampuz  et al., 2003). For reasons that are poorly understood, but which 
may be related to high intracranial pressure, children with severe malaria frequently exhibit 
abnormal posturing, a sign indicating severe brain damage (Idro  et al., 2007). Malaria has 
been  found  to  cause  cognitive  impairments,  especially  in  children.  It  causes  widespread 
anemia during  a  period  of  rapid  brain  development  and  also  direct  brain  damage.  This 
neurologic  damage  results  from  cerebral  malaria  to  which  children  are  more  vulnerable 
(Boivin, 2002).
Consequences of severe malaria  include  coma and death if  untreated,  young children and 
pregnant women are especially vulnerable. Splenomegaly (enlarged spleen), severe headache, 
cerebral  ischemia,  hepatomegaly (enlarged liver),  hypoglycemia,  and hemoglobinuria  with 
renal failure may occur (Trampuz  et al., 2003). Renal failure may cause  blackwater fever, 
where hemoglobin from lysed red blood cells leaks into the urine (Idro et al., 2007). Severe 
malaria can progress extremely rapidly and cause death within hours or days. In the most 
severe  cases  of  the  disease  fatality  rates  can  exceed  20%,  even  with  intensive  care  and 
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treatment (Kain  et al., 1998). In endemic areas, treatment is often less satisfactory and the 
overall fatality rate for all cases of malaria can be as high as one in ten (Mockenhaupt et al., 
2004). Over the longer term, developmental impairments have been documented in children 
who have suffered episodes of severe malaria (Trampuz et al., 2003). Chronic malaria is seen 
in both P. vivax and P. ovale, but not in P. falciparum. Here, the disease can relapse months 
or years after exposure, due to the presence of latent parasites (hypnozoites) in the liver (Kain 
et  al., 1998).  Severe malaria  is  almost exclusively  caused by  P. falciparum infection  and 
usually arises 6-14 days after infection.
2.5. Diagnosis
Direct microscopic examination of intracellular parasites on stained blood films is the gold 
standard for definitive diagnosis in nearly all  settings.  However,  several other approaches 
exist or are in development, some of which are discussed here.
2.5.1. Microscopy
Simple  light  microscopic  examination  of  Giemsa  stained  blood  films  is  the  most  widely 
practiced  and  useful  method  for  definitive  malaria  diagnosis.  Advantages  include 
differentiation between species, quantification of the parasite density and ability to distinguish 
clinically  important  asexual  parasite  stages  from gametocytes  which  may  persist  without 
causing  symptoms  (WHO,  1991).  These  advantages  can  be  critical  for  proper  case-
management and evaluating parasitological response to treatment. Specific disadvantages are 
that slide collection, staining, and reading can be time-consuming and microscopists need to 
be trained and supervised to ensure consistent reliability. While availability of microscopic 
diagnosis has been shown to reduce drug use in some trial settings (Chanda et al., 2009). Any 
programme aimed at  improving the availability  of reliable  microscopy should also retrain 
clinicians in the use and interpretation of microscopic diagnosis. 
Another  method is  a  modification  of light  microscopy called the Quantitative  Buffy Coat 
Method  (QBCTM,  Becton-Dickinson).  Originally  developed  to  screen  large  numbers  of 
specimens for complete blood cell counts, this method has been adapted for malaria diagnosis 
(Levine et al., 1989). The technique uses microhaematocrit tubes precoated with fluorescent 
acridine  orange  stain  to  highlight  malaria  parasites.  With  centrifugation,  parasites  are 
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concentrated at a predictable location. Advantages to QBC are that less training is required to 
operate  the  system than  for  reading  Giemsa-stained  blood  films  and  the  test  is  typically 
quicker to perform than normal light microscopy. Disadvantages are that electricity is always 
required, special equipment and supplies are needed, the per-test cost is higher than simple 
light microscopy, and species-specific diagnosis is not reliable. Field trials have shown that 
the QBC system may be marginally more sensitive than conventional microscopy under ideal 
conditions (Levine et al., 1989; Tharavanij, 1990). 
2.5.2. Clinical (presumptive) Diagnosis 
Although  reliable  diagnosis  cannot  be  made  on  the  basis  of  signs  and  symptoms  alone 
because of the non-specific nature of clinical malaria, clinical diagnosis of malaria is common 
in many malarious areas (WHO, 1997). In much of the malaria-endemic world, resources and 
trained health personnel are so scarce that presumptive clinical diagnosis is the only realistic 
option (Smith et al., 1994). Clinical diagnosis offers the advantages of ease, speed, and low 
cost. In areas where malaria is prevalent, clinical diagnosis usually results in all patients with 
fever and no apparent other cause being treated for malaria. This approach can identify most 
patients who truly need antimalarial treatment, but it is also likely to misclassify many who do 
not (Olivar  et al., 1991). Over-diagnosis contributes considerably to misuse of antimalarial 
drugs  (Ogungbamigbe  et  al.,  2008).  Considerable  overlap  exists  between  the  signs  and 
symptoms of  malaria  and other  frequent  diseases,  especially  acute  lower  respiratory  tract 
infection and can greatly increase the frequency of misdiagnosis and mistreatment (Redd et  
al., 1992).
Attempts to improve the specificity of clinical diagnosis for malaria by including signs and 
symptoms other than fever or history of fever have met with only minimal success (Smith et  
al., 1994). The Integrated Management of Childhood Illnesses (IMCI) programme defined an 
algorithm that has been developed in order to improve diagnosis and treatment of the most 
common childhood illnesses in areas relying upon relatively unskilled health care workers 
working  without  access  to  laboratories  or  special  equipment.  With  this  algorithm,  every 
febrile child living in a “high-risk” area for malaria should be considered to have, and be 
treated for, malaria. “High risk” has been defined in IMCI Adaptation Guides as being any 
situation where as little as 5% of febrile children between the ages of 2 and 59 months are 
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parasitaemic (WHO, 1997), a definition that will likely lead to significant over-diagnosis of 
malaria in areas with low to moderate malaria transmission.
2.5.3. Antigen detection tests (rapid or “dipstick” diagnostic tests)
A third  diagnostic  approach  involves  the  rapid  detection  of  parasite  antigens  using  rapid 
immunochromatographic  techniques.  Multiple  experimental  tests  have  been  developed 
targeting  a  variety  of  parasite  antigens  (WHO,  1996;  Bloland,  2001).  A  number  of 
commercially  available  kits  (e.g.  ParaSight-F®,  Becton-Dickinson;  Malaquick®,  ICT, 
Sydney, New South Wales, Australia) are based on the detection of the histidine-rich protein 
2 (HRP-II) of  P. falciparum.  Compared with light microscopy and QBC, this test yielded 
rapid and highly sensitive diagnosis of P. falciparum infection (WHO, 1996; Craig and Sharp, 
1997).  Advantages  to  this  technology  are  that  no special  equipment  is  required,  minimal 
training is needed, the test and reagents are stable at ambient temperatures and no electricity is 
needed.  The principal  disadvantages  are  a  currently  high per-test  cost and an inability  to 
quantify the density of infection. Furthermore, for tests based on HRP-II, detectable antigen 
can persist for days after adequate treatment and cure; therefore, the test cannot adequately 
distinguish a resolving infection from treatment failure due to drug resistance, especially early 
after treatment (WHO, 1996). 
Additionally, a test based on detection of a specific parasite enzyme (lactate dehydrogenase or 
pLDH) has been developed (OptiMAL®, Flow Inc. Portland, OR, USA) and reportedly only 
detects viable parasites, which if true, eliminates prolonged periods of false positivity post-
treatment (Makler et al., 1998; Palmer et al., 1999). Newer generation antigen detection tests 
are able to distinguish between falciparum and non-falciparum infections, greatly expanding 
their  usefulness in areas where non-falciparum malaria  is transmitted frequently (Bloland, 
2001).
2.5.4. Molecular tests
Detection of parasite genetic material through polymerase-chain reaction (PCR) techniques 
has become a more frequently used tool in the diagnosis of malaria, as well as the diagnosis 
and surveillance of drug resistance in malaria. Specific primers have been developed for each 
of the four species of human malaria. One important use of this new technology is in detecting 
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mixed infections or differentiating between infecting species when microscopic examination 
is inconclusive (Beck, 1999). In addition, improved PCR techniques could prove useful for 
conducting  molecular  epidemiological  investigations  of  malaria  clusters  or  epidemics 
(Purfield  et al.,  2004). Primary disadvantages to these methods are overall  high cost, high 
degree of training required, need for special equipment, absolute requirement for electricity, 
and potential for cross-contamination between samples (Berzins and Anders, 1999).
2.5.5 Serology
Techniques  also  exist  for  detecting  anti-malaria  antibodies  in  serum specimens.  Specific 
serological markers have been identified for each of the four species of human malaria. A 
positive test generally indicates a past infection. Serology is not useful for diagnosing acute 
infections because detectable levels of anti-malaria antibodies do not appear until weeks into 
infection  and persist  long after  parasitaemia  has resolved.  Moreover,  the test  is  relatively 
expensive, and not widely available (Bloland, 2001).
2.6. Antimalarial Drugs
For the past 50 years, there have been two main classes of antimalarial  agents in use, the 
antifolates and the cinchona alkaloids or the quinoline-containing drugs (Philips, 2001). The 
quinoline-containing  drugs  include the cinchona alkaloids,  quinine and quinidine,  and the 
aminoalcohol quinine analogues mefloquine (a 4-quinoline methanol) and halofantrine (a 9-
phenathrene methanol), which are recent introductions (ter Kuile 1993; Philips 2001). There 
are also the 8-aminoquinoline primaquine, which is used for its gametocidal effect and its 
action on the liver stage of P. Vivax, and the 4-aminoquinolines, chloroquine and its relative 
amodiaquine  (White,  1997).  The  antifolates  include  the  diaminopyrimidines,  such  as 
pyrimethamine and trimethoprim; the biguanides, represented by proguanil (cycloguanil) and 
chlorproguanil; and the sulfa drugs, including the sulfonamides and the sulfones. 
2.6.1. Quinine and related compounds 
Quinine is the oldest and most famous anti-malarial (Dorvault, 1982). It has a long history 
stretching from Peru, to the discovery of the Cinchona tree and the potential uses of its bark, 
to the current day and a collection of derivatives that are still frequently used in the prevention 
and treatment of malaria (Segurado et al., 1997). Quinine is an alkaloid that acts as a blood 
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schizonticidal and  weak  gametocide against  Plasmodium  species.  As  an  alkaloid,  it  is 
accumulated  in  the  food  vacuoles of  Plasmodium,  especially  P.  falciparum.  It  acts  by 
inhibiting the hemozoin biocrystallization, thus facilitating an aggregation of cytotoxic heme. 
Quinine is less effective and more toxic as a blood schizonticidal agent than  Chloroquine; 
however it is still very effective and widely used in the treatment of acute cases of severe P. 
falciparum (Foley and Tilley, 1998). It is especially useful in areas where there is known to be 
a  high  level  of  resistance  to  Chloroquine,  Mefloquine and  sulfa  drug combinations  with 
pyrimethamine (Foley  and Tilley, 1998). Quinine is also used in post-exposure treatment of 
individuals  returning  from  an  area  where  malaria  is  endemic (Foley  and  Tilley,  1997). 
Quinine,  along with  its  dextroisomer,  Quinidine,  has  been the  drug of  last  resort  for  the 
treatment of malaria, especially severe disease. 
Quinimax and Quinidine are the two most commonly used alkaloids related to Quinine, in the 
treatment  or prevention  of Malaria.  Quinimax is  a combination  of four alkaloids  (namely 
Quinine, Quinidine, Cinchoine and Cinchonidine) (Mills and Bone, 2000). This combination 
has been shown in several studies to be more effective than Quinine, supposedly due to a 
synergistic action between the four Cinchona derivatives. Quinidine is a direct derivative of 
Quinine.  It  is  a  distereoisomer,  thus  having  similar  anti-malarial  properties  to  the  parent 
compound.  Quinidine  is  recommended  only  for  the  treatment  or  severe  cases  of  malaria 
(Foley and Tilley, 1998).
Chloroquine
Chloroquine is a 4-aminoquinolone derivative of quinine, first synthesized in 1934 and has 
since been the most widely used antimalarial drug until recently (WHO, 2001). Historically, it 
has been the drug of choice for the treatment of non-severe or uncomplicated malaria and for 
chemoprophylaxis. It is believed to reach high concentrations in the vacuoles of the parasite, 
which, due to its alkaline nature, raises the internal  pH. It controls the conversion of toxic 
heme to  hemozoin by inhibiting  the  biocrystallization of  hemozoin (Lobel  and Campbell, 
1986) thus  poisoning  the  parasite  through  excess  levels  of  toxicity.  Other  potential 
mechanisms through which it may act include interfering with the biosynthesis of parasitic 
nucleic acids, the formation of a chloroquine-haem or chloroquine-DNA complex. It was the 
original prototype from which most other methods of treatment are derived (Foley and Tilley, 
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1997).  It  is  also  the  least  expensive,  best  tested  and  safest  of  all  available  drugs.  The 
emergence  of  drug  resistant  parasitic  strains  is  rapidly  decreasing  its  effectiveness 
(Rieckmann et al., 1978; Wellems and Plowe, 2001); however it is still the first-line drug of 
choice  in  most  sub-Saharan  African countries.  It  is  now  suggested  that  it  is  used  in 
combination with other antimalarial drugs to extend its effective usage.
The most significant level of activity found is against all forms of the schizonts (with the 
obvious  exception  of  chloroquine-resistant  P.  falciparum and  P.  vivax strains)  and  the 
gametocytes of  P. vivax, P. malariae,  P. ovale as well as the immature gametocytes of  P. 
falciparum. Chloroquine also has a significant anti-pyretic and anti-inflammatory effect when 
used to treat P. vivax infections, thus it may still remain useful even when resistance is more 
widespread  (Alene  and  Bennett,  1996).  A  slightly  different  drug  called  nivaquine or 
chloroquine phosphate was also invented (Bloland 2001).
Amodiaquine
Amodiaquine is a 4-aminoquinolone anti-malarial drug similar in structure and mechanism of 
action to Chloroquine (Winstanley et al., 1987). It is thought to be more effective in clearing 
parasites in uncomplicated malarial than Chloroquine, thus leading to a faster rate of recovery 
(Olliaro and Taylor. 2002). However, some fatal adverse effects of the drug were noted during 
the 1980’s, thus reducing its usage in chemoprophylaxis. The WHO’s advice on the subject 
maintained that the drug should be used when the potential risk of not treating an infection 
outweighs the risk of developing side effects (Basco, 1991). It has also been suggested that it 
is  particularly  effective  and less  toxic  than  other  combination  treatments  in  HIV positive 
patients (Parise  et al., 1998). Adverse reactions are generally similar in severity and type to 
that seen in Chloroquine treatment. In addition,  bradycardia, itching, nausea, vomiting and 
some abdominal pain have been recorded. Some blood and hepatic disorders have also been 
seen in a small number of patients (Olliaro et al., 1996).
Mefloquine
Mefloquine was developed during the  Vietnam War and is chemically related to quinine. It 
was developed to protect American troops against multi-drug resistant P. falciparum. It is a 
very potent blood schizonticide with a long half-life (Mockenhaupt, 1995). It is thought to act 
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by  forming  toxic  heme  complexes  that  damage  parasitic  food  vacuoles.  Mefloquine 
(Lariam®) is effective in prophylaxis and for acute therapy (Palmer  et al., 1993). It is now 
strictly used for resistant strains (and is usually combined with Artesunate) (van Vugt et al., 
1998). It has been linked with an increased number of stillbirths (Palmer et al., 1993) and is 
not  recommended  for  use  during  the  first  trimester,  although  considered  safe  during  the 
second and third trimesters. Mefloquine frequently produces side effects, including nausea, 
vomiting,  diarrhea,  abdominal  pain  and  dizziness.  Several  associations  with  neurological 
events  have  been  made,  namely  affective and  anxiety  disorders,  hallucinations,  sleep 
disturbances,  psychosis,  toxic  encephalopathy,  convulsions  and  delirium.  Moreover 
cardiovascular effects  have been recorded with bradycardia  and  sinus arrhythmia (Ridley, 
1997)
Atovaquone
Atovaquone  is  a  hydroxynapthoquinone  that  is  currently  being  used  most  widely  for  the 
treatment  of  opportunistic  infections  in  immunosuppressed  patients.  It  is  effective  against 
chloroquine-resistant  P.  falciparum,  but  because  when  used  alone,  resistance  develops 
rapidly, atovaquone is usually given in combination with proguanil (Looareesuwan, 1996). A 
fixed  dose  antimalarial  combination  of  250mg  atovaquone  and  100mg  proguanil 
(MalaroneTM)  was introduced to market  worldwide and was additionally  being distributed 
through a donation programme (Foege,  1997). Two drugs originally  synthesized in China 
were recommended for field trials. Pyronaridine was reported to be 100% effective in one trial 
in Cameroon (Ringwald et al., 1996); however, it was only between 63% and 88% effective 
in  Thailand  (Looareesuwan,  1996).  Lumefantrinel,  a  fluoromethanol  compound,  was  also 
produced  as  a  fixed  combination.  Atovaquone produces  no  side-effects  such  as  the 
cardiovascular effect with mefloquine which can trigger heart rhythm problems. 
Primaquine
Primaquine is a highly active 8-aminoquinolone that was used in treating all types of malaria 
infection (Olliaro and Trigg, 1995). It was most effective against gametocytes but also acts on 
hypnozoites, blood schizonticytes and the dormant plasmodia in  P. vivax and  P. ovale. It is 
the only known drug to cure both relapsing malaria infections and acute cases (Looareesuwan, 
1996). The mechanism of action is thought to mediate some effect through creating oxygen 
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free  radicals that  interfere  with the  plasmodial  electron  transport  chain during  respiration 
(Bloland  et  al.,  1997).  There  are  few  significant  side  effects  such  as  anorexia,  nausea, 
vomiting,  cramps,  chest  weakness,  anaemia,  some  suppression  of  myeloid activity  and 
abdominal pains; In cases of over-dosage granulocytopenia may occur (Bruce-Chwatt,, 1985).
Halofantrine
Halofantrine was developed by the  Walter  Reed Army Institute  of Research in the 1960s 
(Mills and Bone, 2000). It is a phenanthrene methanol, chemically related to Quinine and acts 
as a blood schizonticide effective against all Plasmodium parasites (ter Kuile et al., 1993). Its 
mechanism of action is similar to other anti-malarials. Cytotoxic complexes are formed with 
ferritoporphyrin XI that cause plasmodial membrane damage (Bloland, 2001). Despite being 
effective  against  drug  resistant  parasites,  Halofantrine  was  not  commonly  used  in  the 
treatment  (prophylactic  or  therapeutic)  of  malaria  due  to  its  high  cost,  very  variable 
bioavailability  and most importantly  it  has been shown to have potentially  high levels of 
cardiotoxicity (Nosten et al., 1993). A popular drug based on halofantrine is Halfan. 
2.6.2 Antifolate drugs
This class of drugs includes effective casual antimalarial prophylactic and therapeutic agents, 
some  of  which  act  synergistically  when  used  in  combination.  They  are  of  various 
combinations of dihydrofolate-reductase inhibitors (proguanil, chlorproguanil, pyrimethamine 
and trimethoprim) and sulfa drugs (dapsone, sulfalene,  sulfamethoxazole,  sulfadoxine,  and 
others).  Although these  drugs  have  antimalarial  activity  when  used  alone,  parasitological 
resistance can develop rapidly (Kupferschmidt et al., 1988). When combined, they produce a 
synergistic effect on the parasite and can be effective even in the presence of resistance to the 
individual  components  (Kublin  et  al., 2002).  Typical  combinations  include 
sulfadoxine/pyrimethamine  (SP  or  Fansidar1),  sulfalene-pyrimethamine  (metakelfin)  and 
sulfamethoxazole-trimethoprim (co-trimoxazole). A newer antifolate combination drug which 
is a combination of chlorproguanil and dapsone, also known as Lapdap, has a much more 
potent  synergistic  effect  on  malaria  than  existing  drugs  such  as  SP.  Benefits  of  this 
combination include a greater cure rate, even in areas currently experiencing some level of SP 
resistance,  a  lower  likelihood  of  resistance  developing  because  of  a  more  advantageous 
pharmacokinetic and pharmacodynamic profile and probable low cost (Kublin et al., 2002).
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Sulphadoxine Pyrimethamine
Sulfadoxine-pyrimethamine (SP) has been widely used as first-line therapy for uncomplicated 
P. falciparum malaria throughout sub-Saharan Africa, because of its affordability, its ease of 
administration  and  until  recently,  its  effectiveness.  It  is  currently  the  only  option  for 
intermittent treatment of malaria during pregnancy (McCollum et al., 2006). SP, which has 
potent  efficacy  against  chloroquine-resistant  and  pyrimethamine-resistant  P.  falciparum,  
became available in 1971 and became the standard second-line therapy against chloroquine-
resistant falciparum malaria. Pyrimethamine acts by inhibiting dihydrofolate reductase in the 
parasite, thus preventing the biosynthesis of purines and pyrimidines and therefore halting the 
processes of DNA synthesis, cell division and reproduction. It acts primarily on the schizonts 
during  the  hepatic  and  erythrocytic  phases  (Kuznetsov et  al., 1984).  The  action  of 
sulphadoxine is focused on inhibiting the use of para-aminobenzoic acid during the synthesis 
of dihydropteroic acid. When combined the two key stages in DNA synthesis in the plasmodia 
are prevented. 
Proguanil
Proguanil (Chloroguanadine)  is  a  biguanide;  a  synthetic  derivative  of  pyrimidine.  It  was 
developed in 1945 by a British Antimalarial research group (Mills and Bone, 2000). It has 
many  mechanisms  of  action  but  primarily  is  mediated  through  conversion  to  the  active 
metabolite cycloguanil pamoate. This inhibits the malarial dihydrofolate reductase enzyme. 
Its most prominent effect is on the primary tissue stages of  P. falciparum, P. vivax and  P. 
ovale. It has no known effect against  hypnozoites therefore is not used in the prevention of 
relapse.  It  has  a  weak  blood  schizonticidal  activity  when  combined  with  Atovaquone (a 
hydroxynaphthoquinone). Proguanil is used as a prophylactic treatment in combination with 
another drug, most frequently Chloroquine (Kublin et al., 2002). Proguanil has been used in 
combination with dapsone for prophylaxis and treatment (Shanks et al., 1992; Mutabingwa et  
al., 2005) and recently, proguanil/dapsone has been combined with artesunate (Nzila  et al., 
2002).  There are very few side effects to Proguanil, with slight hair loss and mouth ulcers 
being occasionally reported following prophylactic use.
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2.6.3 Antibiotics
Tetracycline and derivatives such as doxycycline are very potent antimalarials and are used 
for  both  treatment  and  prophylaxis  (Kremsner  et  al., 1994).  In  areas  where  response  to 
quinine has deteriorated, tetracyclines are often used in combination with quinine to improve 
cure rates. Clindamycin has been used but offers only limited advantage when compared to 
other available antimalarial drugs as parasitological response is slow and recrudescence rates 
are high (Kremsner et al., 1994). 
 Doxycycline
Doxycycline is  a  Tetracycline compound derived  from  Oxytetracycline.  The tetracyclines 
were one of the earliest  groups of antibiotics to be developed and are still  used widely in 
many types of infection. It is a bacteriostatic agent that acts to inhibit the process of protein 
synthesis by binding to the 30S ribosomal subunit thus preventing the 50s and 30s units from 
bonding (Kremsner  et  al., 1989).  Doxycycline  is  used primarily  for  chemoprophylaxis  in 
areas where quinine resistance exists. It can be used in resistant cases of uncomplicated  P. 
falciparum but has a very slow action in acute malaria. The most commonly experienced side 
effects are permanent enamel hypoplasia, transient depression of bone growth, gastrointestinal 
disturbances and some increased levels of photosensitivity. Due to its effect on bone and tooth 
growth it is not used in children under 8, pregnant or lactating women and those with a known 
hepatic dysfunction (Kremsner et al., 1994). Tetracycline is only used in combination for the 
treatment of acute cases of P. falciparum infections due to its slow onset. Unlike Doxycycline 
it  is  not  used  in  chemoprophylaxis.  Oesophageal  ulceration,  gastrointestinal  upset  and 
interferences with the process of  ossification and depression of bone growth are known to 
occur. The majority of side effects associated with Doxycycline are also experienced.
Clindamycin
Clindamycin is a derivative of Lincomycin, with a slow action against blood schizonticides. It 
is  only  used  in  combination  with Quinine  in  the  treatment  of  acute  cases  of  resistant  P. 
falciparum infections and not as a prophylactic (Kremsner et al., 1989; 1994)
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2.6.4. Artemisinin compounds
Artemisinin is a Chinese herb (Qinghaosu) that has been used in the treatment of fevers for 
over 1,000 years (WHO, 1996), thus predating the use of Quinine in the western world. It is 
derived  from  the  plant  Artemisia  annua,  with  the  first  documentation  as  a  successful 
therapeutic agent in the treatment of malaria in 340 AD (Mueller  et al.  2000; 2004). The 
active compound was isolated first in 1971 and named Artemsinin (Mills and Bone, 2000). It 
is a sesquiterpene lactone with a chemically rare peroxide bridge linkage, which is thought to 
be responsible for the majority of its  anti-malarial  action (Hien and White,  1993).  It  has 
proven to be effective against all forms of multi-drug resistant P. falciparum, thus every care 
is taken to ensure compliance and adherence together with other behaviours associated with 
the development of resistance. It is also only given in combination with other anti-malarials.
Artemesinin  has a  very rapid action  and the vast  majority  of  acute patients  treated  show 
significant  improvement  within  1-3  days  of  receiving  treatment.  It  has  demonstrated  the 
fastest  clearance  of all  anti-malarials  currently used and acts  primarily  on the trophozoite 
phase,  thus  preventing  progression  of  the  disease.  It  is  converted  to  active  metabolite 
dihydroartemesinin  that  then  inhibits  the  Sarcoplasmic/Endoplasmic  Reticulum Calcium 
ATPase (SERCA) encoded by  P. falciparum  (Eckstein-Ludwig  et al., 2003). It was one of 
many candidates then tested by Chinese scientists from a list of nearly 200 traditional Chinese 
medicines for treating malaria. It was the only one that was effective, but it was found that it 
cleared malaria parasites from their bodies faster than any other drug in history.  Artemisia  
annua is a common herb and has been found in many parts of the world, including along the 
Potomac River, in Washington, D.C (Hien and White, 1993).
A  number  of  sesquiterpine  lactone  compounds  have  been  synthesized  from  the  plant 
Artemisia annua (artesunate, artemether, arteether) (Mills and Bone, 2000). These compounds 
are used for treatment of severe malaria and have shown very rapid parasite clearance times 
and faster fever resolution than occurs with quinine.  Artemisinin drugs first  introduced in 
South-East Asia have proven to be well tolerated and the most potent of antimalarials (White,  
1999).  They  exhibit  the  following  properties: rapid  significant  reduction  of  parasite 
biomass, rapid  resolution  of  clinical  symptoms, effective  against  multidrug  resistant  P. 
falciparum and reduction of gametocyte carriage, which may reduce transmission. However, 
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artemisinin drugs have a very short half-life and thus a multiple dose regimen of seven days is 
required to achieve an acceptable cure rate (WHO, 2003).
In some areas of South-East Asia, combinations of artemisinins and mefloquine offer the only 
reliable  treatment  for  uncomplicated  malaria,  due  to  the  development  and  prevalence  of 
multidrug resistant  falciparum malaria (White, 1999). Combination therapy (an artemisinin 
compound given in combination with another antimalarial), typically a long half-life drug like 
mefloquine) has reportedly been responsible for inhibiting intensification of drug resistance 
and for decreased malaria transmission levels in South-East Asia (Price et al., 1996; White, 
1999). Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination (ACT) 
recommended by the WHO for treating  P. falciparum  malaria in Africa (Sodiomon  et al., 
2009).
Artemether is a methyl ether derivative of dihydroartemesinin. It is similar to artemesinin in 
mode of action but demonstrates a reduced ability as a hypnozoiticidal compound, instead 
acting more significantly to decrease gametocyte carriage. Similar restrictions are in place, as 
with  artemesinin,  to  prevent  the  development  of  resistance,  therefore  it  is  only  used  in 
combination therapy for severe acute cases of drug-resistant P. falciparum. It was discovered 
in  1982  (Dorvault,  1982).  Artesunate,  discovered  in  1983  (Mills  and  Bone,  2000)  is  a 
hemisuccinate derivative of the active metabolite dihydroartemisin. Currently it is the most 
frequently  used  of  all  the  artemesinin-type  drugs.  Its  only  effect  is  mediated  through  a 
reduction in the gametocyte transmission. It is used in combination therapy and is effective in 
cases of uncomplicated P. falciparum. 
Dihydroartemisinin is the active metabolite to which Artemisinin is reduced. It is the most 
effective Artemisinin compound and the least  stable (Krettli,  2001). It  has a strong blood 
schizonticidal action and reduces gametocyte transmission. It is used for therapeutic treatment 
of cases of resistant and uncomplicated P. falciparum. As with artesunate, no side effects to 
treatment have thus far been recorded. 
27
Arteether is an ethyl ether derivative of dihydroartemisinin. It is used in combination therapy 
for cases of uncomplicated resistant P. falciparum (Krettli, 2001). No side effects have been 
recorded. 
2.7 COMBINATION THERAPY WITH ANTIMALARIALS
The problem of the development of malaria resistance must be weighed against the essential 
goal of anti-malarial care; that is to reduce morbidity and mortality. Thus a balance must be 
reached that attempts to achieve both goals whilst not compromising either too much by doing 
so.  The  most  successful  attempts  so  far  have  been  in  the  administration  of  combination 
therapy. The key driver for combination antimalarial therapy is the need to slow development 
of acquired drug resistance to a New Chemical Entity (NCE) and so maintain high levels of 
efficacy for a longer period of time. This is best  achieved  by combining molecules which 
individually have high levels of efficacy (WHO, 2001)
Combination  therapy  can  be  defined  as,  ‘the  simultaneous  use  of  two  or  more  blood 
schizonticidal drugs with independent modes of action and different biochemical targets in the 
parasite’ (Price et al., 1999).  Much evidence has supported the use of combination therapies. 
The use of two antimalarial  drugs simultaneously,  especially  when the antimalarials  have 
different mechanisms of action, has the potential for inhibiting the development of resistance 
to  either  of  the  components.  The  efficacy  of  a  combination  of  a  4-aminoquinoline  drug 
(chloroquine  or  amodiaquine)  with  Sulfadoxine/Pyrimethamine  (SP)  has  been  reviewed 
(McIntosh and Greenwood, 1998). It  was found that the addition of either  chloroquine or 
amodiaquine to SP marginally improved parasitological clearance (compared with SP alone). 
The  studies  reviewed  were  mostly  done  in  areas  and  at  times  when  both  SP  and 
Chloroquine/Amodiaquine retained a fair amount of efficacy, and it is not clear from these 
studies how well such a combination would act in areas where one of the components was 
significantly  compromised.  However  several  problems  prevent  the  wide  use  in  the  areas 
where its use is most advisable. These include: problems identifying the most suitable drug 
for different epidemiological situations, the expense of combined therapy (it is over 10 times 
more  expensive  than  traditional  mono-therapy),  how  soon  the  programmes  should  be 
introduced and problems linked with policy implementation and issues of compliance (WHO, 
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2001). The combinations of drugs currently prescribed can be divided into two categories: 
Non-artemesinin and quinine-based combinations and artemesinin based combinations.
2.7.1 Non-Artemesinin based combinations
Sulfadoxine-pyrimethamine plus Amodiaquine: This is a combination that has been shown 
to  produce  a  faster  rate  of  clinical  recovery  than  SP  and  Chloroquine  (McIntosh  and 
Greenwood 1998). However there are serious adverse reactions associated which have limited 
its distribution. It is thought to have a longer therapeutic lifetime than other combinations and 
may  be  a  more  cost-effective  option  to  introduce  in  areas  where  resistance  is  likely  to 
develop. 
Sulfadoxine-Pyrimethamine  plus  Mefloquine:  This  is  produced  as  a  single  dose  pill 
(Fansimef®)  and has  obvious  advantages  over  some of  the  more complex regimes.  This 
combination of drugs has very different pharmokinetic properties with no synergistic action. 
This characteristic is potentially thought to delay the development of resistance; however it is 
counteracted by the very long half  life  of Mefloquine which could exert  a  high selection 
pressure  in  areas  where  intensive  malaria  transmission  occurs.  It  is  also  an  expensive 
combination. 
Tetracycline or Doxycycline plus Quinine:  Despite the increasing levels of resistance to 
Quinine this combination have proven to be particularly efficacious (Kremsner et al., 1994). 
The longer half-life of the Tetracycline component ensures a high cure rate. Problems with 
this regime include the relatively complicated drug regimen, where Quinine must be taken 
every 8 hours for 7 days. Additionally, there are severe side effects to both drugs (Cinchonism 
in Quinine) and Tetracyclines are contraindicated in children and pregnant women. For these 
reasons this combination is not recommended as first-line therapy but can be used for non-
responders who remain able to take oral medication. 
 2.7.2 Artemesinin-based combinations 
Artemesinin has a very different mode of action from conventional anti-malarials. This makes 
it particularly useful in the treatment of resistant infections (Mueller et al., 2000). However, in 
order  to  prevent  the  development  of  resistance  to  this  drug  it  is  only  recommended  in 
combination with another non-artemesinin based therapy. It produces a very rapid reduction 
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in the parasite biomass with an associated reduction in clinical symptoms and is known to 
cause a reduction in the transmission of gametocytes thus decreasing the potential  for the 
spread of resistant alleles.  Artemisinin combination therapy (ACT) has been widely adopted 
as first-line treatment for uncomplicated falciparum malaria (Ashley et al., 2007; Nosten and 
White,  2007).  Although  these  drug  combinations  appear  to  be  safe  and  well-tolerated, 
experience with their use in Africa is still limited (Talisuna et al., 2006; Staedke et al., 2008). 
Artesunate and chloroquine combination has been thoroughly tested in randomized controlled 
trials and has demonstrated that it is well tolerated with few side effects (Nosten and White, 
2007).  However,  in  one  study there  was less  than  85% cure in  areas  where Chloroquine 
resistance was known. It is not approved for use in combination therapy and is unadvised in 
areas of high  P. falciparum resistance.  Artesunate and Amodiaquine combination has also 
been  tested  and  proved  to  be  more  efficacious  and  similarly  well  tolerated  than  the 
Chloroquine combination. The cure rate was greater than 90%, potentially providing a viable 
alternative where levels of Chloroquine resistance are high (Sodiomon et al., 2009). The main 
disadvantage is a suggested link with neutropenia (Mutabingwa et al., 2005). 
Artesunate and mefloquine have been used as an efficacious first-line treatment regimen in 
areas  of  Thailand  for  many  years  (Adjuik  et  al., 2004).  Mefloquine  is  known  to  cause 
vomiting  in  children  and  it  induces  some  neuropsychiatric  and  cardiotoxic  effects, 
interestingly these adverse reactions  seem to be reduced when the drug is  combined with 
Artesunate, it is suggested that this is due to a delayed onset of action of Mefloquine. This is  
not  considered  a  viable  option  to  be  introduced  in  Africa  due  to  the  long  half-life  of 
Mefloquine,  which potentially  could exert  a high selection pressure on parasites (Bloland, 
2001). 
Artemether and Lumefantrine (Coartem®, Riamet®, and Lonart®) is a combination that has 
been extensively tested in 16 clinical trials, proving effective in children less than 5years and 
has  been  shown  to  be  better  tolerated  than  Artesunate  plus  Mefloquine  combinations 
(Mutabingwa et al., 2005). There are no serious side effects documented but the drug is not 
recommended in pregnant or lactating women due to limited safety testing in these groups. 
This is the most viable option for widespread use and is available in fixed-dose formulae thus 
increasing compliance and adherence (Lefevre et al., 2001). 
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Artesunate and Sulfadoxine-Pyrimethamine is a well tolerated combination but the overall 
level of efficacy still depends on the level of resistance to Sulfadoxine and Pyrimethamine 
thus  limiting  its  usage  (WHO,  2001).  Piperaquine-dihydroartemisinin-trimethoprim 
(Artecom®) alone and in combination with Primaquine has been studied in resistant areas of 
China and Vietnam (Yeka  et al., 2008). The drug has been shown to be highly efficacious 
(greater than 90%) even to strains resistant to Primaquine. More information is required on 
safety and tolerability in pregnant women and children and toxicology data. Pyronaridine and 
Artesunate has been tested and was shown to have a clinical response rate of 100% in one trial 
in Hainan (an area with high levels of P. falciparum resistance to Pyronaridine) (Nosten and 
White, 2007). Chlorproguanil-Dapsone and Artesunate (Lapdap plus) is the most tested drug 
currently under development and could be introduced in African countries imminently. It is 
not  recommended  as  a  monotherapy  due  to  concerns  of  resistance  developing,  thus 
threatening the future use of related compounds (Nosten and White, 2007). 
2.7.3. Traditional Antimalarial Herbs
The use of plants for therapeutic purposes dates back to the human history (Ogbonna et al., 
2008). Medicinal plants, since time immemorial, have been used in virtually all cultures as a 
source of medicine (Hoareau and Dasilva, 1999) and for a long time, natural products were 
the only sources of medication (Bourdy et al., 2008). Several medicinal plants have been used 
locally  to  treat  malaria  infection.  Some  of  such  plants  are  Enantia  chloranta,  Nauclea  
natifolia,  Salacia  Nitida  (Ogbonna  et  al.,  2008),  Acalypha  fruticosa,  Azadirachta  indica, 
Cissus  rotundifolia, Echium  rauwalfii,  Dendrosicyos  socotrana and  Boswellia  elongate  
(Merlin, 2004; Clarkson  et al.,  2004;  Alshwash  et al.,  2007),  Cymbopogon giganteus and 
Morinda  lucida  etc  .Medicinal  plants  such  as  Momordica  charantia (Ejirin  wewe),  M 
balsamina (Ejirin),  Ageratum conyzoides  (Imi Eshu), Ocimum gratissimum Cardiospermum 
grandiofiorum  (Ako Ejirin), Diospyros monbuttensis (Egun Eja) etc have been used to treat 
one ailment or the other in Africa, especially Nigeria (Awe and Makinde, 1997; Azas et al., 
2002 Otimenyin et al., 2008).
The  urgency  generated  by  drug-resistant strains  of malaria  parasites  has  accelerated 
antimalarial drug research over the last two decades. While synthetic pharmaceutical agents 
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continue  to dominate research, attention has increasingly been directed  to natural products 
(Etkin, 2003). The success  of artemisinin, isolated from Artemisia annua and its derivatives 
for  the  treatment of resistant  malaria  has  focused  attention  on  the  plants  as a  source  of 
antimalarial  drugs  (Tan  et  al.,  1998).  Moreover,  plants  have  been  the  basic  source  of 
sophisticated traditional medicine systems for thousands of years and were instrumental to 
early pharmaceutical drug discovery and industry (Elujoba et al., 2005). The world's poorest 
are the worst affected, and many treat themselves with traditional herbal medicines. These are 
often  more  available  and affordable, and sometimes  are  perceived  as  more  effective  than 
conventional antimalarial drugs (Merlin, 2004). 
Ethnobotanical information about antimalarial plants used in traditional herbal medicine, is 
essential for further evaluation of the efficacy  of plant antimalarial remedies and efforts are 
now  being  directed  towards  discovery  and  development  of new chemically  diverse 
antimalarial agents (Clarkson et al., 2004). Several rural dwellers depend on traditional herbal 
medicine for treatment  of many infectious diseases including malaria (Ali  et al., 2004). The 
reputed efficacies of these plants have been recognized and passed on from one generation to 
the other.
About 75% of the population in Africa does not have direct access to chemical treatment, 
such  as  chloroquine,  but  they  have  access  to  traditional  medicine  for  treating  fevers. 
Treatment with these remedies has suffered a number of deficiencies;  diagnosis is often a 
problem, identification of plant extracts may be insecure and the chemical content of extracts 
may vary considerably  (Azas  et  al.,  2002).  Natural  products isolated  from plants  used in 
traditional  medicine,  which have potent  antiplasmodial  action  in  vitro,  represent  potential 
sources of new antimalarial  drugs (Wright  et al,. 1994; Gasquet  et al., 1993). It had been 
advocated that direct crude drug formulation of the herbs following toxicological absolution 
may not only produce dosage forms faster but will also lead to cheaper and more affordable 
drugs for the communities that need them (Elujoba, 1998). Also, there is a belief that these 
medicines are safe because they are natural and have been used traditionally over a period of 
time (Sofowora, 1993; Willcox et al., 2003). 
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Plant  materials  remain  an  important  resource  to  combat  serious  diseases  in  the  world 
(Tshibangu et al., 2002) and pharmacognostic investigations of plants are carried out to find 
novel drugs or templates for development of new therapeutic agents (König, 1992). Moreover 
herbs can be highly effective for treating malaria if government can educate those involved in 
the practice regarding the normal dose to be taken before getting well. Therefore, government 
should provide subvention for the Ministry of Health incorporating National Agency for Food 
and Drug Administration and Control (NAFDAC) to go into more Malaria research in local 
herb just to develop new and more effective drug for prevention and control, particularly in 
view of the rapid spread of drug resistance.  Nevertheless,  much work need to be done to 
educate the community and the producers of indigenous herbal products to strictly adhere to 
environmental hygiene
2.8 Antimalarial Drug Resistance
Resistance to antimalarial drugs has been described for two of the four species of malaria 
parasite that naturally infect humans, P. falciparum and P. vivax (Nguyen-Dinh et al., 1981; 
Singh, 2000). P. falciparum has developed resistance to nearly all antimalarials in current use, 
although the geographical  distribution  of resistance  to  any single antimalarial  drug varies 
greatly  (Wongsrichanalai  et  al.,  2002;  Talisuna  et  al.,  2004).  Chloroquine-resistant 
falciparum malaria has been described everywhere that  P. falciparum malaria is transmitted 
(Verdrager, 1986; Wernsdorfer, 1991; Wellems and Plowe, 2001; Sidhu et al., 2002; White 
2004; ) except for malarious areas of Central America (north-west of the Panama Canal), the 
island of Hispaniola, and limited areas of the Middle East and Central Asia (Bloland, 2001). 
Verdrager (1995) has described Localized permanent epidemics as the genesis of chloroquine 
resistance in P. falciparum. 
Sulfadoxine/Pyrimethamine (SP) resistance occurs frequently in South-East Asia and South 
America  and  is  more  prevalent  in  Africa  as  the  drug  is  increasingly  being  used  as  a 
replacement for chloroquine (Price et al., 1999; Purfield et al., 2004). Mefloquine resistance 
is frequent in some areas of South-East Asia and has been reported in the Amazon region of 
South America and sporadically  in Africa (Mockenhaupt,  1995). Cross-resistance between 
halofantrine and mefloquine is suggested by reduced response to halofantrine when used to 
treat mefloquine failures (ter Kuile et al., 1993).  Noedl and others (2008) in a recent study 
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have  shown that  artemisinin  is  losing  its  potency  in  Cambodia  and increased  efforts  are 
required to prevent artemisinin-resistant malaria from spreading across the globe.  
2.8.1 Definition of antimalarial drug resistance
Antimalarial drug resistance has been defined as the “ability of a parasite strain to survive 
and/or multiply despite the administration and absorption of a drug given in doses equal to or 
higher than those usually recommended but within tolerance of the subject” (WHO, 1972). 
This definition was later modified to specify that the drug in question must “gain access to the 
parasite or the infected red blood cell for the duration of the time necessary for its normal 
action”  (Wernsdorfer  and Wernsdorfer,  1995).  Most researchers  interpret  this  as  referring 
only to persistence of parasites after treatment doses of an antimalarial rather than prophylaxis 
failure, although the latter is a useful tool for early warning of the presence of drug resistance 
(Lobel and Campbell, 1986).
This definition of resistance requires demonstration of malaria parasitaemia in a patient who 
has  received  an  observed  treatment  dose  of  an  antimalarial  drug  and  simultaneous 
demonstration  of  adequate  blood  drug  and  metabolite  concentrations  using  established 
laboratory methods (such as high performance liquid chromatography) or in vitro tests (Basco 
and Ringwald, 2000). In practice, this is rarely done with  in vivo  studies.  In vivo  studies of 
drugs  for  which true  resistance  is  well  known (such as  chloroquine)  infrequently  include 
confirmation of drug absorption and metabolism. Demonstration of persistence of parasites in 
a patient receiving directly  observed therapy is usually considered sufficient.  Some drugs, 
such as  mefloquine,  are  known to  produce  widely  varying  blood levels  after  appropriate 
dosing and apparent resistance can often be explained by inadequate blood levels (Slutsker, 
1990; Basco, 1991). 
2.8.2 Malaria treatment failure
Drug resistant parasites are often used to explain malaria treatment failure. However, they are 
two different clinical scenarios. These are failure to clear  parasitaemia and recover from an 
acute clinical episode when a suitable treatment has been given and anti-malarial resistance in 
its true form. A distinction must be made between a failure to clear malarial parasitaemia or 
resolve clinical disease following a treatment with an antimalarial drug and true antimalarial 
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drug resistance. While drug resistance can cause treatment failure, not all treatment failures 
are due to drug resistance (Plowe, 2003). Many factors can contribute to treatment failure 
including  incorrect  dosing,  non-compliance  with  duration  of  dosing  regimen,  poor  drug 
quality, drug interactions, poor or erratic absorption, and misdiagnosis. Probably all of these 
factors, while causing treatment failure (or apparent treatment failure) in the individual, may 
also  contribute  to  the  development  and  intensification  of  true  drug  resistance  through 
increasing  the  likelihood  of  exposure  of  parasites  to  suboptimal  drug  levels  (Ariey  and 
Robert, 2003).
2.8.3 Mechanisms of antimalarial resistance
In general, resistance appears to occur through spontaneous mutations that confer reduced 
sensitivity to a given drug or class of drugs. For some drugs, only a single point mutation is 
required to confer resistance, while for other drugs, multiple mutations appear to be required 
(Lobel and Campbell,  1986). Provided the mutations are not deleterious to the survival or 
reproduction of the parasite, drug pressure will remove susceptible parasites while resistant 
parasites survive (Watkins and Mosobo, 1993). Single malaria cases have been found to be 
made  up  of  heterogeneous  populations  of  parasites  that  can  have  widely  varying  drug 
response  characteristics,  from  highly  resistant  to  completely  sensitive  (Thaithong,  1983). 
Similarly,  within  a  geographical  area,  malaria  infections  demonstrate  a  range  of  drug 
susceptibility. Over time, resistance becomes established in the population and can be very 
stable; persisting long after specific drug pressure is removed. The biochemical mechanism of 
resistance  has  been well  described for  chloroquine,  the  antifolate  combination  drugs,  and 
atovaquone (Looareesuwan, 1996; Alene and Bennett, 1996; Bloland, 2001; Alifrangis et al., 
2003).
2.8.3.1 Chloroquine resistance
The first type of resistance to be acknowledged was to Chloroquine in Thailand in 1957 (Mills 
and Bone, 2000). As the malaria parasite digests haemoglobin, large amounts of a toxic by-
product are formed. The parasite polymerizes this by-product in its food vacuole, producing 
non-toxic  haemozoin  (malaria  pigment).  It  is  believed that  resistance  of  P. falciparum  to 
chloroquine is related to an increased capacity for the parasite to expel chloroquine at a rate 
that does not allow chloroquine to reach levels required for inhibition of haem polymerization 
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(Foley and Tilley, 1997). This chloroquine efflux occurs at a rate of 40 to 50 times faster 
among resistant parasites than sensitive ones (Martin et al., 1987).
Further  evidence  supporting  this  mechanism  is  provided  by  the  fact  that  chloroquine 
resistance can be reversed by drugs which interfere with this efflux system (Martin  et al., 
1987). It is unclear whether parasite resistance to other quinoline antimalarials (amodiaquine, 
mefloquine,  halofantrine,  and quinine)  occurs  via  similar  mechanisms  but  resistances are 
thought to have occurred by similar mechanisms (Foley and Tilley, 1997).
2.8.3.2 Antifolate combination drugs
Antifolate combination drugs, such as sulfadoxine plus pyrimethamine, act through sequential 
and synergistic blockade of two key enzymes involved with folate synthesis. Pyrimethamine 
and related compounds inhibit the step mediated by dihydrofolate reductase (DHFR) while 
sulfones and sulfonamides inhibit the step mediated by dihydropteroate synthetase (DHPS) 
(Bruce-Chwatt, 1985; Kublin  et al.,  2002). Specific gene mutations encoding for resistance 
mutations have been associated with varying degrees of resistance to antifolate combination 
drugs (Plowe et al., 1998; Marks et al., 2005). Talisuna et al in Uganda [Talisuna et al.,, 
2004] have shown higher levels of resistance to  chloroquine  and  SP  in  zones  of  higher 
transmission  intensity. On  the  other  hand,  history shows  that chloroquine  resistance 
emerged  first  in  low  transmission zones and that antifolate resistance  has  increased  more 
rapidly  in  low  transmission  areas  (White 2004).
2.9 Spread of resistance
There is no single factor that confers the greatest degree of influence on the spread of drug 
resistance,  but  a  number  of  plausible  causes  associated  with  an  increase  have  been 
acknowledged. These include aspects of economics, human behaviors, pharmacokinetics, and 
the biology of vectors and parasites. The most influential causes are examined below:
2.9.1 Biological influences on resistance 
The biological influences are based on the parasite’s ability to survive the presence of an anti-
malarial thus enabling the persistence of resistance and the potential for further transmission 
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despite treatment. In normal circumstances parasites that persist after treatment are destroyed 
by the host’s immune system, therefore factors that act to reduce the elimination of parasites 
could  facilitate  the  development  of  resistance  (Bloland,  2001).  This  explains  the  poorer 
response  associated  with  immunocompromised individuals,  pregnant  women  and  young 
children.         
Based on data on the response of sensitive parasites to antimalarial  drugs  in vitro  and the 
pharmacokinetic  profiles  of  common  antimalarial  drugs,  there  is  thought  to  always  be  a 
residuum of parasites that are able to survive treatment (Wernsdorfer, 1991). Under normal 
circumstances, these parasites are removed by the immune system. Factors that decrease the 
effectiveness of the immune system in clearing parasite residuum after treatment also appear 
to  increase  survivorship  of  parasites  and  facilitate  development  and  intensification  of 
resistance. This mechanism has been suggested as a significant contributor to resistance in 
South-East Asia, where parasites are repeatedly cycled through populations of non-immune 
individuals  (Verdrager,  1986,  1995).  The  non-specific  immune  response  of  non-immune 
individuals is less effective at clearing parasite residuum than the specific immune response of 
semi-immune  individuals  (White,  1997).  The  same  mechanism  may  also  explain  poorer 
treatment  response  among  young  children  and  pregnant  women  (White,  1997).  Among 
refugee children in the former Zaire, those who were malnourished (low weight for height) 
had  significantly  poorer  parasitological  response  to  both  chloroquine  and  SP  treatment 
(Wolday  et  al., 1995).  Similarly,  evidence  from prevention  of  malaria  during  pregnancy 
suggests that parasitological response to treatment among individuals infected with the human 
immunodeficiency  virus  (HIV)  may also  be  poor.  HIV-seropositive  women  require  more 
frequent  treatment  with SP during pregnancy in order  to  have the same risk of  placental 
malaria as is seen among HIV-seronegative women (Parise et al., 1998). Some characteristics 
of  recrudescent  or  drug resistant  infections  appear  to  provide  a  survival  advantage  or  to 
facilitate  the spread of resistance conferring genes in a population (White., 1999). In one 
study,  patients  experiencing chloroquine treatment  failure  had recrudescent  infections  that 
tended to be less severe or even asymptomatic (Handunnetti et al., 1996). Schizont maturation 
may also be more efficient among resistant parasites (Lobel and Campbell, 1986; Warsame et  
al., 1991). 
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There has been evidence to suggest that certain parasite-vector combinations can alternatively 
enhance  or  inhibit  the  transmission  of  resistant  parasites,  causing  ‘pocket-like’  areas  of 
resistance. In  South-East  Asia,  two important  vectors,  Anopheles  stephensi  and  A.  dirus, 
appear to be more susceptible to drug-resistant malaria parasites than to drug sensitive malaria 
parasites (Wilkinson et al., 1976; Sucharit et al., 1977). In Sri Lanka, researchers found that 
patients  with  chloroquine-resistant  malaria  infections  were  more  likely  to  have 
gametocytaemia than those with sensitive infections and that the gametocytes from resistant 
infections were more infective to mosquitoes (Handunnetti  et al., 1996). The reverse is also 
true; some malaria vectors may be somewhat refractory to drug-resistant malaria, which may 
partially explain the pockets of chloroquine sensitivity that remain in the world in spite of 
very similar human populations and drug pressure as found in Haiti (Bloland et al., 1997). 
Many antimalarial drugs in current usage are closely related chemically and development of 
resistance  to  one  can  facilitate  development  of  resistance  to  others.  Chloroquine  and 
Amodiaquine are both 4-aminoquinolines  and cross-resistance between these two drugs is 
well known (Hall, 1975; Basco, 1991). Development of resistance to mefloquine may also 
lead to resistance to halofantrine and quinine (Foley and Tilley, 1998). Antifolate combination 
drugs have similar action and widespread use of SP for the treatment of malaria may lead to 
increased  parasitological  resistance  to  other  antifolate  combination  drugs  (Watkins  and 
Mosobo, 1993). Development of high levels of SP resistance through continued accumulation 
of DHFR mutations may compromise the useful life span of newer antifolate combination 
drugs such as chlorproguanil/dapsone (LapDap) even before they are brought into use. This 
increased risk of resistance due to SP use may even affect non malarial pathogens as the use 
of  SP  for  treatment  of  malaria  had  been  found  to  result  in  increased  resistance  to 
trimethoprim/sulfamethoxazole among respiratory pathogens (Hastings, 2003). 
There is an interesting theory that development of resistance to a number of antimalarial drugs 
among some falciparum parasites produces a level of genetic plasticity that allows the parasite 
to rapidly adapt to a new drug, even when the new drug is not chemically related to drugs 
previously experienced (Rathod et al., 1997). The underlying mechanism of this plasticity is 
currently  unknown,  but  this  capacity  may help explain the rapidity  with which strains  of 
falciparum develop resistance to new antimalarial drugs. The choice of using a long half-life 
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drug  (SP,  Mefloquine)  in  reference  to  one  with  a  short  half-life  (Chloroquine,  LapDap, 
Quinine)  has  the  benefit  of  simpler,  single  dose  regimens  which  can  greatly  improve 
compliance or make directly observed therapy feasible (Lefevre et al., 2001). Unfortunately, 
that same property may increase the likelihood of resistance developing, due to prolonged 
elimination  periods  (Newton  et  al.,  2006).  Parasites  from new infections  or  recrudescent 
parasites from infections that did not fully clear will be exposed to drug blood levels that are 
high  enough  to  exert  selective  pressure  but  are  insufficient  to  provide  prophylactic  or 
suppressive protection  (Wernsdorfer,  1991).  When blood levels  drop below the  minimum 
inhibitory  concentration (the level  of drug that  fully inhibits  parasite  growth),  but remain 
above  the  concentration  of  drug  that  produces  5%  inhibition  of  parasite  growth  (EC5), 
selection of resistant parasites occurs.  This selection was illustrated in one study in Kenya 
that  monitored  drug  sensitivity  of  parasites  reappearing  after  SP  treatment  (Watkins  and 
Mosobo, 1993). Parasites reappearing during a period when blood levels were below the point 
required to clear pyrimethamine-resistant parasites, but still above that level required to clear 
pyrimethamine-sensitive parasites, were more likely to be pyrimethmine-resistant than those 
reappearing  after  levels  had  dropped  below  the  level  required  to  clear  pyrimethamine-
sensitive parasites (Watkins and  Mosobo, 1993). This period of selective pressure lasts for 
approximately one month for mefloquine, whereas it is only 48 hours for quinine. In areas of 
high malaria transmission, the probability of exposure of parasites to drug during this period 
of selective pressure is high (Trape and Rogier, 1996). In Africa, for instance, people can be 
exposed to as many as 300 infective bites per year;  in rare cases,  even as much as 1000 
infective bites per year and during peak transmission, as many as five infective bites per night 
(Trape and Rogier, 1996).
Mismatched  pharmacokinetics  can  also  play  a  role  in  facilitating  the  development  of 
resistance.  For instance the elimination half-life of pyrimethamine is  between 80 and 100 
hours and is between 100 and 200 hours for sulfadoxine, leaving an extended period when 
sulfadoxine is “unprotected” by synergy with pyrimethamine (Watkins and Mosobo, 1993). 
This  sort  of  mismatched  pharmacokinetics  is  even more  apparent  in  the  mefloquine  plus 
sulfadoxine-pyrimethamine  combination  used  in  Thailand  where  mefloquine  has  an 
elimination half-life of approximately 336 to 432 hours (Palmer  et al., 1993; McIntosh and 
Greenwood, 1998). It is apparent that there are more genetically distinct clones per person in 
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areas of more intense transmission than in areas of lower transmission (Babiker and Walliker, 
1997). However, the interpretation of this and its implications for development of resistance 
has  variously  been  described  as  resistance  being  more  likely  in  low-transmission 
environments  (Paul  and  Day,  1998),  high-transmission  environments  (Mackinnon,  1997; 
Mackinnon and Hastings, 1998; Babiker and Walliker, 1997), or either low- or high- but not 
intermediate-transmission environments (Hastings 1997; Hastings and Mckinnon, 1998).
 
The relationship between transmission intensity and parasite genetic structure is obviously 
complex  and  subject  to  other  confounding/contributing  factors  (Hastings  and  Mckinnon, 
1998). What is clear is that the rate at which resistance develops in a given area is sensitive to 
a number of factors beyond mere intensity of transmission. Such factors are initial prevalence 
of mutations, intensity of drug pressure, population movement between areas, the nature of 
acquired  immunity  to  the  parasite  or  its  strains,  etc.  However,  reducing  the  intensity  of 
transmission  will  likely  facilitate  prolonging  the  useful  life  span  of  drugs  (Hastings  and 
Mckinnon, 1998).
2.9.2 Programmatic influences on resistance
Programmatic influences on development of antimalarial drug resistance include overall drug 
pressure,  inadequate  drug  intake  (poor  compliance  or  inappropriate  dosing  regimens), 
pharmacokinetic and pharmacodynamic properties of the drug or drug combination, and drug 
interactions  (Wernsdorfer  and  Wernsdorfer,  1995).  Additionally,  reliance  on  presumptive 
treatment can facilitate the development of antimalarial drug resistance. Overall drug pressure 
especially  that  exerted  by  programmes  utilizing  mass  drug  administration  (e.g  Eko  free 
malaria  programme,  Federal  government  Malaria  intervention  programme using  Coartem) 
probably has the greatest impact on development of resistance (Payne, 1988; Wernsdorfer, 
1999). Studies have suggested that resistance rates are higher in urban and periurban areas 
than rural communities, where access to and use of drug is greater (Ettling et al., 1995). 
Confusion over proper dosing regimen has been described. In Thailand the malaria control 
programme recommended 2 tablets (adult dose) of SP for treating malaria based on studies 
suggesting that this was effective. Within a few years, this was no longer effective and the 
programme increased the regimen to 3 tablets (Price  et al.,  1996). Although unproven, this 
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may have contributed to the rapid loss of SP efficacy there. Similar confusion over the proper 
SP dosing regimen exists in Africa (Salako, 1998). To simplify treatment, many programmes 
dose  children  based  on  age  rather  than  weight  and  depending  on  the  regimen  being 
recommended, this has been shown to produce systematic under dosing among children of 
certain weight and age groups (Plowe, 2003). 
The use of presumptive treatment for malaria has the potential for facilitating resistance by 
greatly increasing  the  number  of  people  who  are  treated  unnecessarily  but  will  still  be 
exerting selective pressure on the circulating parasite population (Wernsdorfer et al, 1994). In 
some areas and at some times of the year, the number of patients being treated unnecessarily 
for malaria  can be very large (Persidis, 2000). Concurrent treatment with other drugs can 
increase  the  likelihood  of  treatment  failure  and  may  contribute  to  development  of  drug 
resistance.  For instance,  folate administration for treatment  of anaemia and possibly when 
used as a routine supplement during pregnancy can increase treatment failure rates (Ballereau, 
1997).  Similarly,  concurrent  illness  and  malnourishment  may  have  an  influence  on  drug 
resistance (Payne, 1988). 
Drug quality has also been implicated in ineffective treatment and possibly drug resistance 
(Shakoor  et  al.,  1997).  Either  through  poor  manufacturing  practices,  intentional 
counterfeiting, or deterioration due to inadequate handling and storage, drugs may not contain 
sufficient quantities of the active ingredients. In an analysis of chloroquine and antibiotics 
available in Nigeria and Thailand, between 37% and 40% of samples assayed had substandard 
content  of  active  ingredients,  mostly  from poor  manufacturing  practices  (Shakoor  et  al., 
1997). Another study in Africa found chloroquine stored under realistic tropical conditions 
lost at least 10% of its activity in a little over a year (Ballereau, 1997).
2.10 Detection of resistance
In general, four basic methods have been routinely used to study or measure antimalarial drug 
resistance:  in  vivo,  in  vitro,  animal  model  studies,  and molecular  characterization  (Basco, 
2007). Additionally, less rigorous methods have been used, such as case reports, case series, 
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or passive surveillance. Much discussion has occurred regarding the relative merits of one test 
over  another,  with  the  implication  always  being  that  one  type  of  test  should  be  used 
preferentially.  Careful  consideration  of  the  types  of  information  each  yields  indicates, 
however, that these are complementary, rather than competing, sources of information about 
resistance. Recognition of drug resistance (or, treatment failure) in individual patients is made 
difficult in many settings by operational issues such as availability and quality of microscopy. 
Especially in Africa, where presumptive diagnosis and treatment for malaria is most common, 
detection of treatment failures also tends to be presumptive (persistence or reappearance of 
clinical  symptoms in a patient  recently  receiving  malaria  treatment).  Because of the non-
specific nature of clinical signs and symptoms of malaria and the many other causes of febrile 
disease, this can lead to a false sense that a particular drug is not working when it is, or, 
potentially, that an ineffective drug is working when it is not. In cases where microscopy is 
used, presence of parasitaemia in a supposedly fully treated patient may indicate treatment 
failure, but is not necessarily evidence of drug resistance.
2.10.1 In vivo tests
An  in  vivo  test  consists  of  the  treatment  of  a  group  of  symptomatic  and  parasitaemic 
individuals with known doses of drug and the subsequent monitoring of the parasitological 
and/or clinical response over time (Basco, 2007). One of the key characteristics of  in vivo 
tests is the interplay between host and parasite. Diminished therapeutic efficacy of a drug can 
be masked by immune clearance of parasites among patients with a high degree of acquired 
immunity (White, 1997). Of the available tests, in vivo tests most closely reflect actual clinical 
or epidemiological situations i.e. the therapeutic response of currently circulating parasites 
infecting the actual population in which the drug will be used. Because of the influence of 
external factors (host immunity, variations of drug absorption and metabolism, and potential 
misclassification  of  reinfections  as  recrudescences),  the  results  of  in  vivo  tests  do  not 
necessarily reflect the true level of pure antimalarial drug resistance. However, this test offers 
the best information on the efficacy of antimalarial treatment under close to actual operational 
conditions. This should be expected to occur among clinic patients if provider and patient 
compliance  is  high.  The original  methods  for  in  vivo  tests  required prolonged periods  of 
follow-up (minimum of 28 days) and seclusion of patients in screened rooms to prevent the 
possibility of re-infection. These methods have since been modified extensively and the most 
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widely  used  methods  now  involve  shorter  periods  of  follow-up  (7  to  14  days)  without 
seclusion, under the assumption that reappearance of parasites within 14 days of treatment is 
more  likely  due  to  recrudescence  rather  than  re-infection  (WHO,  1996b).  Additional 
modifications reflect the increased emphasis on clinical response in addition to parasitological 
response.  Traditionally,  response  to  treatment  was  categorized  purely  on  parasitological 
grounds as sensitive, resistance I (RI), RII, and RIII (WHO, 1996). Later modifications have 
combined, to varying extent, parasitological and clinical indicators (WHO, 1996). 
Since anaemia can be a major component  of malaria illness,  in vivo  methodologies allow 
investigation  of  haematological  recovery  after  malaria  therapy  (Boland,  2001).  Failure  of 
complete parasitological clearance, even in situations where recurrence of fever is rare, can be 
associated  with  lack  of  optimal  haematological  recovery  among  anaemic  patients. 
Standardization is however a limitation in this methodology. Major differences in sample size, 
enrolment  criteria,  exclusion  criteria,  length  and  intensity  of  follow-up,  loss-to-follow-up 
rates, and interpretation and reporting of results are apparent in published papers on in vivo 
trials (Ringwald and Basco, 1999). These differences make it difficult, if not impossible, to 
compare results from one study to another with any level of confidence (Bloland, 2001). The 
methodology  currently  being  used  and  promoted,  especially  in  sub-Saharan  Africa,  is  a 
system that emphasizes clinical response over parasitological response (WHO, 1996). Close 
adherence to this protocol does provide comparable data; however, these data are not readily 
comparable  to  data  collected  using other  in  vivo  methods.  Although not called for in the 
protocol, categorization of the parasitological response using the standard WHO definitions 
(WHO 1996) would allow some ability to compare to historical levels and provide useful 
parasitological results that would aid in interpreting the clinical results.
2.10.2 In vitro tests
From the point of view of a researcher interested in pure drug resistance, in vitro tests avoid 
many of the confounding factors which influence in vivo tests by removing parasites from the 
host and placing them into a controlled experimental  environment.  In the most frequently 
used procedure, the micro-technique, parasites obtained from a finger-prick blood sample are 
exposed in microtitre plates to precisely known quantities of drug and observed for inhibition 
of maturation into schizonts (Rieckmann et al., 1978; Jenson, 1988; Basco, 2007). This test 
more accurately reflects “pure” antimalarial drug resistance. Multiple tests can be performed 
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on isolates,  several  drugs can be assessed simultaneously,  and experimental  drugs can be 
tested. In addition, falciparum erythrocytic parasites can be evaluated in-vitro. However, the 
test has certain significant disadvantages. The correlation of  in vitro  response with clinical 
response in patients is neither clear nor consistent, and the correlation appears to depend on 
the  level  of  acquired  immunity  within  the  population  being  tested.  Prodrugs,  such  as 
proguanil, which require host conversion into active metabolites, cannot be tested. Neither can 
drugs that  require  some level  of synergism with the host’s  immune system (Golenda and 
Rosenberg, 1997). These tests are technologically more demanding and relatively expensive, 
which makes them potentially more difficult to adapt successfully to routine work in the field. 
In vitro assays for the sensitivity of human malaria parasites to antimalarial drugs provide 
information complementary to that derived from the epidemiology of drug-resistant malaria 
(Basco and Ringwald, 2007). Its principles were initially based on a suboptimal short-term 
culture method reported in 1912 which was applied for the WHO macrotest system in the 
1960s ( Rieckmann et al., 1978) and used until the 1980s. The principles of in vitro culture 
underwent a major modification in 1976, when a new method for continuous culture of  P. 
falciparum  was  reported  by  Trager  &  Jensen  (1976).  The  essential  components  of  the 
complete blood-medium mixture are Roswell Park Memorial Institute (RPMI) 1640 medium 
buffered with N-(2-hydroxyethyl) piperazine-N´-(2-ethanesulfonic acid) (HEPES) and sodium 
bicarbonate,  human serum (or serum substitutes,  including animal  sera and lipid enriched 
bovine albumin) and P. falciparum-infected human erythrocytes. This technical improvement 
led to the elaboration of several  in vitro assay systems in the late 1970s and in the 1980s, 
including the WHO microtest  system (morphological  assay),  the 48-h test  (morphological 
assay) and the radioisotope microtest (Basco, 2007). Over the past few years, two novel  in  
vitro drug sensitivity assays have been evaluated:  an enzyme-linked immunosorbent  assay 
(ELISA) with monoclonal antibodies directed against either plasmodial lactate dehydrogenase 
(LDH) or  histidine-rich  protein  II  (HRP II)  and a  fluorometric  assay  with  DNA-binding 
fluorescent dyes (WHO, 1997). These two assays are non-morphological and non-radioactive 
and are also based on Trager & Jensen’s (1976) culture method.
2.10.3 Animal model studies
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This type of test is, in essence, an in vivo test conducted in a non-human animal model and 
therefore, is influenced by many of the same extrinsic factors as in vivo tests (Bloland, 2001). 
The influence of host immunity is minimized by using lab-reared animals or animal-parasite 
combinations unlikely to occur in nature, although other host factors would still be present. 
These tests allow for the testing of parasites which cannot be adapted to in vitro environments 
(provided a suitable animal host is available) and the testing of experimental drugs not yet 
approved for use in humans. A significant disadvantage is that only parasites that can grow in, 
or are adaptable to, non-human primates can be investigated.
2.10.4 Molecular techniques
These tests offer promising advantages to the methods described above. Molecular tests use 
polymerase chain reaction (PCR) to indicate the presence of mutations encoding biological 
resistance  to  antimalarial  drugs  (Plowe  et  al.,  1998).  Theoretically,  the  frequency  of 
occurrence of specific gene mutations within a sample of parasites obtained from patients 
from a given area could provide an indication of the frequency of drug resistance in that area 
analogous to information derived from in vitro  methods (Basco, 2007). Advantages include 
the need for only small amounts of genetic material as opposed to live parasites, independence 
from host and environmental factors and the ability to conduct large numbers of tests in a 
relatively  short  period  of  time (Beck,  1999).  Disadvantages  include  the obvious  need for 
sophisticated equipment and training and the fact that gene mutations that confer antimalarial 
drug resistance are currently known or debated for only a limited number of drugs primarily 
for dihydrofolate  reductase inhibitors  (pyrimethamine),  dihydropteroate  synthase inhibitors 
(sulfadoxine), and chloroquine (Plowe et al., 1998). Confirmation of the association between 
given mutations and actual drug resistance is difficult,  especially when resistance involves 
more than one gene locus and multiple mutations (Sidhu et al 2002). 
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2.10.5 Case reports and passive detection of treatment failure
Additional methods for identifying or monitoring antimalarial drug resistance include the use 
of case reports or case series of spontaneously reported treatment failure. In general, these 
methods require far less investment in time, money and personnel and can be done on an 
ongoing basis by individual health care centers (Bloland, 2001). They suffer however, from 
presenting a potentially biased view of drug resistance primarily because denominators are 
typically unknown and rates of resistance cannot be calculated. Nonetheless, case reports can 
be  useful  and  may  indicate  a  problem that  should  be  confirmed  using  one  of  the  other 
methods. In the United States for instance, case reports, especially when occurring in clusters, 
of  prophylaxis  failure  have  been  used  to  help  formulate  recommendations  for 
chemoprophylaxis of non-immune travellers to endemic areas (White, 1999). 
Another method that has been used is passive detection of treatment failure. In this system, 
patients are treated following usual treatment guidelines and told to come back to the clinic or 
hospital  if  symptoms  persist  or  return.  Those  cases  which  do  return  are  considered  to 
represent  the  population  of  treatment  failures.  Because  this  system  does  not  ensure 
compliance with treatment regimens through directly observed therapy and does not attempt 
to locate and determine the outcome of patients who do not return on their own, data are 
seriously biased. In a study conducted in Ethiopia and Eritrea using this method, only 1706 
(4.3%) out of 39824 patients returned to the clinic (Alene and Bennett, 1996). The assumption 
was that those patients who did not return did not have resistant parasites, yielding a very low 
prevalence  of  resistance  (1.8%  to  4.8%,  depending  on  region).  These  results  contrast 
dramatically with results from standard 7-days in vivo trials conducted at two sites in Eritrea 
in 1994 (Bloland, 2001) and one site in Ethiopia in 1993–1994 which found between 58% and 
86% RII/RIII level resistance (Tulu, 1996).
2.11 The future: prevention of drug resistance
The future of antimalarial drug resistance and efforts to combat it is defined by a number of 
assumptions. First, antimalarial drugs will continue to be needed long into the future (Breman, 
2001).  No  strategy  in  existence  or  in  development,  short  of  an  unforeseen  scientific 
breakthrough or complete eradication, is likely to be 100% effective in preventing malaria 
infection. Secondly, as long as drugs are used, the chance of resistance developing to those 
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drugs is present (Plowe, 2003). P. falciparum has developed resistance to nearly all available 
antimalarial drugs and it is highly likely that the parasite will eventually develop resistance to 
any drug that is used widely. Thirdly, development of new drugs appears to be taking longer 
than development of parasitological resistance. The development of resistance to antimalarial 
drugs in South-East Asia has been far quicker than the estimated 12 to 17 years it takes to 
develop and market a new antimalarial compound (Ridley, 1997). Fourthly, affordability is an 
essential consideration for any strategy to control drug-resistant malaria, especially in Africa 
(Foster and Phillips 1998; Goodman et al., 1999). 
The future, especially in Africa, will also be defined by how well the central tenets of malaria 
control can be reconciled with the central tenets of control of drug resistance. One of the 
cornerstones of the current approach to malaria control is the provision of prompt, effective 
malaria treatment. In much of Africa, easy access to public sector health care is limited and 
when it is accessible, health care staff are often inadequately trained, insufficiently supplied 
and supported,  ineffectively supervised and poorly motivated (Goodman et al., 2000). One 
response to this situation has been the intentional liberalization of access to drugs; instead of 
relying so heavily on the formal public sector to distribute antimalarial drugs, some people are 
suggesting that the best way to reduce the time between onset of illness and first treatment 
with an antimalarial drug is by making these drugs widely available on the open market, from 
unofficial sources of health care and at the household level (Salako, 1998). This approach is 
gaining  support  internationally.  This  approach  is  also  in  direct  conflict  with  the  primary 
methods for inhibiting development of drug resistance, limited access to and judicious use of 
chemotherapeutic agents. Clearly, some middle ground will need to be identified that will 
improve access to antimalarial drugs for those who need to be treated while at the same time 
reducing the inappropriate use of those same drugs. Prevention strategies can be divided into 
those  aimed  specifically  at  preventing  malaria  infection  and those  aimed  at  reducing  the 
likelihood of development of drug resistance. Reduction of overall malaria infection rates or 
transmission rates have an indirect impact on development of drug resistance by reducing the 
number  of  infections  needing to  be treated  (and therefore,  overall  drug pressure)  and by 
reducing the likelihood that resistant parasites are successfully transmitted to new hosts. The 
transmission reduction methods include the use of insecticide-treated bednets, indoor residual 
insecticide spraying, environmental control (mosquito breeding site or “source” reduction), 
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other  personal  protection  measures  (e.g.  use of repellent  soap or screening windows) and 
chemoprophylaxis  in  defined  populations  (Ariey  and  Robert,  2003).  An  effective  and 
deliverable vaccine would also be greatly beneficial (Good, 2001).
Interventions aimed at preventing drug resistance, generally focus on reducing overall drug 
pressure through more selective use of drugs; improving the way drugs are used and also by 
improving prescribing  by clinicians,  follow-up practices  and patient  compliance;  or  using 
drugs  or  drug  combinations  which  are  inherently  less  likely  to  foster  resistance  or  have 
properties that do not facilitate development or spread of resistant parasites (Plowe, 2003).
In Nigeria, the methods that are widely used to study antimalarial drug resistance are in-vivo 
methods, animal model studies and molecular methods (Oduola et al., 1993; Ogbonna et al., 
2008;  Ogunfowokan  et  al.,  2009).  Using in-vitro sensitivity  test  more  accurately  reflects 
“pure” antimalarial drug resistance, multiple tests can be performed on isolates, several drugs 
can  be  assessed  simultaneously  and  experimental  drugs  can  be  tested  (Basco,  2007).  In 
addition,  falciparum erythrocytic parasites can be evaluated  in-vitro. The method is also a 
good epidemiological tool to assess baseline sensitivity and to monitor the drug response of 
P.  falciparum  (Druilhe  et  al.,  2007).  Moreover,  it  provides  background  information  for 
development and evaluation of drug policies, can be an indicator of future therapeutic failure 
and can also guide on the partner drug in ACT (Basco, 2007).
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CHAPTER THREE
MATERIALS AND METHODS
3.1 Study area: 
This  study  was  carried  out  in  Ogun  State,  located  in  the  tropical  zone  of  Southwestern 
Nigeria. With its state capital in Abeokuta, Ogun State has a land area of 16,409.26 square 
kilometers and a population of 2,759,109 (Unpublished report,  Ministry of Health,  2003). 
Ogun State is bounded on the West by Benin Republic, on the South by Lagos State and the 
Atlantic Ocean, on the East by Ondo State and on the North by Oyo State. The State is made 
up of six ethnic groups viz, Egba, Ijebu, Remo, Egbado, Awori and Egun. The language of the 
majority of the people of Ogun State is Yoruba but this is however broken into scores of 
dialects.  Ogun State is in the transitional zone between the tropical rain forest and derived 
savannah zone in the southwest, Nigeria. The area experiences two seasons, the dry season 
(November to March) and the wet season (April to October). The annual temperature range is 
from 22.8oC to 34.9oC and the mean annual rainfall is about 107.3mm. Malaria is present 
throughout the year with a marked increase during the rainy season (Ojo, 2005). 
3.2 Study subjects
Children between 1-15 years, pregnant women and other adults were included in this study. 
This is because majority of malaria cases occur in children under the age of 12 years, pregnant 
women  are  also  especially  vulnerable.  The  blood  samples  were  collected  and  analyzed 
between April 2008 and June 2009.
3.3 Sampling Procedure
Ogun State, which was the study site, was divided into 4 zones for sample collection. The 4 
zones are 
• Sango – Ota (Yewa)
• Abeokuta (Egba) 
• Ijebu Ode (Ijebu) and
• Sagamu (Remo)
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Fig 2.1 Map of Ogun State, Southwestern Nigeria 
(http://ogunstate.gov.ng/eGovernment/index.php)
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Using the population size of each zone and the rate of prevalence of malaria in the state, the 
sample size for each of the four zones was calculated with a 95% CI and precision level of 5% 
as follows:   n = Z2 P(1-P) 2 /d2       
Where n=sample size
           Z=1.96 at 95% 
           P=Prevalence rate 
           d=Sampling error that can be tolerated (0.05)      
State general hospitals located in the different zones were used as sample collection centers. 
Both in and out patients who presented with uncomplicated malaria  in the hospitals  were 
recruited for the research work. Four thousand and sixty six patients were recruited into this 
study. The total number of subjects recruited in Sango-ota, Abeokuta, Ijebu-ode and Sagamu 
were 1120, 1116, 995 and 835 respectively. The mean age was 19 years (>1 –70) with 93% 
less than 25 years.
3.4 Ethical Consideration
Scientific and Ethical clearance was obtained from the Nigerian Institute of Medical Research 
- Institutional Review Board (NIMR-IRB) and Covenant University Ethics Committee for this 
work. The Ogun State Ministry of health (Hospitals Management Board) was also informed 
and clearance obtained for this study. Written informed consent was obtained from patients 
prior  to  recruitment  into  this  study.  Consent  for  the  children  was  provided  by  the 
parents/guardians while some of the participants provided the assents.
3.5. Sample collection 
Blood samples were collected for malaria screening from both fingerprick and venepuncture . 
This is to check the presence of healthy asexual parasites in the peripheral smear of patients. 
Safety procedures were adopted in the collection of finger-prick blood samples by swabbing 
the  area  to  be  sampled  with  70% alcohol  and  allowing  it  to  dry  before  collection.  The 
bleeding was done in the hospitals by clinicians and medical laboratory scientists. About 2-5 
ml of blood was then drawn (venepuncture) with a sterile disposable syringe and transferred 
to a heparinised centrifuge tube. The blood samples were transported to the laboratory at 40C. 
Drops of peripheral blood were placed on 1.5 x 7.0-cm strips of Whatman (Brentford, United 
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Kingdom) 3MM filter paper so that the blood covered half the length of the strip. The strips 
were air-dried and kept in plastic bags until use. 
3.6 Cryopreservation
The infected blood was centrifuged at 3000 revolutions per minute (rpm) for 10 min in a 
refrigerated  centrifuge.  The supernatant/plasma was removed and cells  were suspended in 
equal volume of cryopreservative. The suspension was distributed into cryotubes and quickly 
frozen  in  cryofreezer  at  -800C  and  then  transferred  into  liquid  nitrogen  (-1960C).  The 
cryopreservative was prepared by adding 28ml glycerol to 72ml of 4.2% Sorbitol in normal 
saline. The solution was sterilized by filtration through a Millipore filter of 0.22µm porosity.
3.7 Processing of Sample
3.7.1 Microscopic examination
Thick and thin films stained with Giemsa were prepared for the microscopic examination of 
the malaria parasite. The thin films were fixed with methanol and all films were stained with 
3% Giemsa stain of pH 7.0 for 30 min as recommended by WHO (WHO, 2000). Blood films 
were  examined  microscopically  using  100X  (oil  immersion)  objectives  as  described  by 
Cheesbrough (2000). The thick films were used to determine the parasite densities while thin 
films  were used to  identify  the parasite  species  and infective  stages.  Parasite  density  per 
microlitre of blood (parasitemia) was estimated from the thick film, taking the number of 
leucocytes per microliter of blood as 8,000 and was expressed as follows: 
                               
                 Parasite count x 8,000 
    Parasite density/µL =              No of WBC counted  
   
3.8. Antimalarial sensitivity testing 
3.8.1 Revival of Cryopreserved parasites
The vial was taken out of the liquid nitrogen tank and thawed quickly in a 370C water bath. 
The content was transferred to a centrifuge tube and centrifuged at 3000rpm for 10min. The 
supernatant was then removed and an equal volume of 3.5% NaCl was added. The suspension 
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was  centrifuged  again  and  the  supernatant  removed.  The  pellet  was  washed  twice  with 
complete medium supplemented with 15%serum.  
3.8.2 In vitro microtest (Mark III Test)
Drug samples were prepared in picomole (pM) quantities according to WHO in vitro micro 
test procedure (WHO, 1990; Druilhe  et al., 2001). Blood collected on heparin was washed 
twice in RPMI 1640 medium (Gibco BRL, Paisley, United Kingdom) and once with complete 
culture  medium  (Appendix  I).  Chloroquine  sulphate,  amodiaquine,  mefloquine,  SP  and 
artemisinin were dosed into 96-well microplates. Stock solutions of chloroquine sulphate (600 
ng/ml)  and  the  other  antimalarial  drugs  (ng/ml)  were  prepared  in  sterile  distilled  water 
(chloroquine, amodiaquine, mefloquine and quinine) or ethanol (sulphadoxine-pyrimethamine 
and artemisinin) and used in twofold dilutions with the culture medium in 96-well culture 
microplates  (Nunc,  Denmark)  to  obtain  nine  final  dilutions  (600  to  2.34  ng/ml  for 
chloroquine) and (appropriate dilution factor was determined for the other drugs). Parasitized 
RBCs was added to each well and to three control wells (without drug) to a final volume of 
250μl/well  at  a  2% hematocrit.  Each  isolate  was  tested  in  duplicate  and  the  plates  were 
incubated at 37°C for 24 – 30 hours. At the end of the assay, the plates were read by preparing 
thick smear from each well and determining the IC50 for each drug using the HN-NonLinn 
software package.
3.9 Antimalarial Activity Testing of Crude Organic Extracts of Medicinal
 Plants: Momordica charantia (Ejirin), Diospyros monbuttensis (Eegun eja) and Morinda 
lucida (Oruwo)
3.9.1 Preparation of Plant Extract
10g of dried extract was dissolved in 50ml alcohol (95%) for 7 days at room temperature. The 
alcohol was allowed to evaporate at room temperature. 10ml Dimethyl sulphoxide (DMSO) 
was added to 10mg of each extract to make 1mg/ml. 
3.9.2 In vitro Test 
The  assay  was  performed  in  duplicate  in  a  96-well  microtiter plate,  according  to WHO 
method [in vitro micro test (Mark III)] that is based on assessing the inhibition  of schizont 
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maturation. RPMI 1640 (Gibco BRL, Paisley, United Kingdom) was the culture medium  used 
for cultivation  of P. falciparum (Flores  et al., 1997). Dilution was prepared from the crude 
plant extract and the final concentrations prepared by dilution were (125, 62.5, 31.25, 15.6, 
7.8,  3.9  and  1.95µg/ml).  Negative  controls  treated  by  solvent  and  positive controls 
(Chloroquine phosphate) were added to each set of experiments.  50µl from the blood mixture 
media was added to each well in plate and incubated in CO2 condition at 37.5°C for 24–30 h. 
After incubation, contents of the wells were harvested and stained for 30 min in a 2% Giemsa 
solution pH 7.2,  after  that  the developed schizonts  were counted  against the  total  asexual 
parasite count of 200. The count process was done in duplicate, and the data were analyzed by 
using HN-NonLin software to estimate IC50
3.10 Molecular studies
Polymerase  Chain  Reaction/Restriction  fragment  Length  Polymorphism (PCR/RFLP)  was 
used  to  determine  the  resistant  genes  and study the  genetic  diversity/genetic  variation  of 
antimalarial resistant Plasmodium falciparum.
3.10.1 DNA extraction 
DNA was extracted from patient blood spotted on the filter paper ("pre-culture") and cultured 
parasites ("post-culture") using the QiaAmp DNA Blood Mini kit Blood and Body Fluid Spin 
Protocol (Qiagen, Valencia, CA). The protocol for the extraction was carried out according to 
manufacturer’s instruction. 
3.10.2 PCR for detection of Pfcrt gene
The oligonucleotides primers were designed from published sequences. For amplification of 
the  1.6-kb fragment  of  pfcrt, the  lower primer was 5'-CCGTTAATAATAAATACAGGC-
3'.The upper primer was 5'-CTTTTAAAAATGGAAGGGTGT-3', (Dorsey et al., 2001). The 
primary  PCR  components, in  a  final  volume  of  20µL,  was  2.5mM  MgCl2,  640µM 
deoxynucleotide  triphosphate  (dNTPs),  buffer  10x,  10pM  of  each primer,  1U  of  Taq 
polymerase (Ampli Taq Gold; Applied Biosystems, Foster City, CA, USA) and 2µL of DNA 
samples. The cycling protocol was as follows: 95°C for 5 min for initial  denaturation;  40 
cycles of 94°C for 30 s, 52°C for 40 s and 72°C for 30 s; and a final extension of 72°C for 5 
min. 
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3.10.3 Nested PCR and RFLP for Pfcrt mutation-specific detection 
Product  from primary PCR (2µl  of  10x dilution)  was used in  a  follow-up, nested,  allele-
specific PCR amplifications to detect the codons for pfcrt 76K or 76T. These diagnostic PCR 
amplifications used a common inner primer pair 5'-GGCTCACGTTTAGGTGGA-3' and 5'-
TGAATTTCCCTTTTTATTTCCAAA-3'  (detects  the  76T  codon)  or  5'-GTTCTTTTAGC 
AAAAATCT-3' (detects the 76K codon). The PCR stages for these diagnostic  amplifications 
were at  94°C for 5 minutes,  followed by 40 cycles  at  94°C for 30 seconds,  52°C for 40 
seconds, and 72°C for  45  seconds and a  final  extension  of  72°C for  5  minutes.  Purified 
genomic DNA from P. falciparum clones HB3 (chloroquine sensitive) and Dd2 (chloroquine 
resistant) were used as positive controls, and water, extracted uninfected blood smears, and 
uninfected blood spots on filter paper were used as negative controls. The PCR products from 
the amplification reactions were evaluated by electrophoresis on 2% agarose gels containing 
ethidium bromide.  
10µl  of  the  nested  PCR  product  reaction  mixture were  treated  directly  with  3U  of  the 
restriction enzyme Apo I for 6 to 16 hours at 50°C as recommended by the  manufacturer (New 
England  Biolabs,  Beverly,  MA).  The  enzyme Apo I  recognise  and  cut  the  76K  codon, 
releasing fragment from product. It does not cut the product containing the 76T codon found 
in chloroquine-resistant P. falciparum. 
3.10.4 PCR and RFLP for detection of Pfmdr1 gene
Gene segments spanning codon 86 of the  Pfmdr1 gene were amplified in 20µl of standard 
PCR  mixture  containing  5µl  of  extracted  DNA and  primers  MDR1  5'-ATGGGTAAA 
GAGCAGAAAGA-3'  and  MDR2  5'-AACGCAAGTAATACATAAAGTCA-3'. The  PCR 
amplification  stages  were  at  94°C for  2  minutes, followed  by  35  cycles  at  94°C for  20 
seconds, 52°C for 10 seconds, 48°C for 10 seconds, and 60°C for 1.5 minutes.  A second, 
nested amplification from this segment was then performed under the same PCR conditions 
using  1µl  of  the  product solution  and  primers  MDR3  5'-TGGTAACCTCAG-
TATCAAAGAA-3' and MDR4 5'-ATAAACCTAAAAAGGAACTGG-3'.
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Presence  of  the  mutant  86Y codon  was  detected  by  digestion  of  8µl  of  the  second 
amplification product solution with 1.5U of Afl III according to the manufacturer’s instruction 
(New  England  Biolabs).  The  products of  restriction  digestion  were  separated  by 
electrophoresis on a 2% agarose gel and detected by staining with ethidium bromide. 
3.10.5 PCR assays for the detection of Pfdhfr and Pfdhps genes
Pfdhfr, and Pfdhps PCRs were performed as described by May and Meyer (2003a) and Marks 
et  a,l (2004).  For  the  Pfdhps  PCR,  two  primers  (primer  Pfdhps-F  5-ATGATTCTTTT 
TCAGATG-3_ and primer Pfdhps-R 5-CCAATTGTGTGATTTGTCCAC-3 were designed to 
amplify 747 bp of the region exhibiting mutations relevant to Sulphadoxine resistance. PCR 
was performed with a volume of 20µl (each primer at 0.2M, dNTPs at 200M, and 1U of  
Hotstar-Taq  with  the  appropriate  buffer  [Qiagen,  Valencia,  Calif.]  and  MgCl2 at  a  final 
concentration of 2.0 mM) and approximately 80ng of template genomic human DNA, with 
parasite DNA concentrations corresponding to the parasite burden in the individual. After an 
initial denaturation (15 min at 95°C), 31 cycles of 30s at 94°C, 40s at 53°C, and 1min at 72°C 
were run. Elongation of the amplicons was completed by a final cycle of 10min at 72°C. 
Subsequently, a nested PCR was performed to increase the yields of the specific amplicons 
using  primers  primer  pfdhps-F1  (5-GTTGAACCTAAACGTGCTG-3)  and  pfdhps-R1  (5-
ATTACAACATTTTGATCATTC-3). 3µl of the primary PCR product was used in a reaction 
volume of 25µl containing 0.2M of each primer, dNTPs at 200M, reaction buffer with MgCl2 
at a final concentration of 2.0 mM, and 1U of Hotstar-Taq). In the nested PCR, a high initial 
annealing  temperature  (AT),  which  ensures  a  high  level  of  specificity  of  initial  primer 
binding, is followed by a gradual decrease in the AT toward the pre-calculated optimal AT. 
The parameters consisted of an initial denaturation step (15 min at 95°C) and 43 cycles of 30s 
at 94°C, the AT for 40 s, and 72°C for 1 min, in which the ATs were 65°C (5 cycles), 60°C (5 
cycles), 56°C (7 cycles), 54°C (13 cycles), and 53°C (13 cycles). Fragment elongation was 
performed by use of a cycle of 10 min at 72°C. The amplicons were monitored for quality and 
the  expected  size  on  1% ethidium bromide-stained  agarose  gels.  Statistical  analysis  (_χ2 
tests) was performed by the use of STATA software (version 8.2; Corp., 
College Station, Tex.).
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3.10.6    PCR and RPLP assay for (SERCA) PfATPase6
P. falciparum positive samples were amplified by PCR using PfATPase6-specific primary and 
nested primer pairs. DNA extract for each sample was subjected to nested PCR amplification 
with primers flanking nucleotide codon 2307of the  PfATPase6 gene. Both the primary and 
secondary reactions comprised 2µl template, 0.25µM primer, 1.5mM MgCl2, 200µM dNTP’s, 
1x PCR buffer and 1U Taq DNA polymerase, in 25µl reactions. Amplification cycles for both 
primary and secondary reactions consisted of an initial denaturation at 940C for 2 minutes, 
followed by 25 cycles  of  denaturation  at  940C for  45  seconds,  annealing  at  460C for  45 
seconds  and  extension  at  650C  for  1  minute,  final  extension  was  run  at  650C  for  2 
minutes.  For primary amplification, the primers are 2307FW 5’-TGA GCA TGG CAC AAG 
TIT 3’; 2307RV- 5’TCA ATA ATA CCT AAT CCA CCT AAA TA-3’.For nested PCR the 
primers are FW-EN 5’-TGA GCA TGG TAG AAG TTT T-3’ and RV-EN 5’- TCA TCT 
GTA TTC TTA ATA ATA TTT AAA TCT GTA CTA-3’ (Zhang et al., 2008). 
Internal  primers  for  the  nested  PCR  amplification  (2307FW-EN  and  2307RV-EN,  were 
engineered to create Csp6 I restriction sites. One site, at  PfATPase6 nucleotide codon 1916, 
serves as the internal control for the restriction digestion assay, which is always cut by the 
enzyme. Csp6 I digestion assay comprised 4µl of secondary PCR amplicon (432bp), 1x buffer 
and 1.5U of Csp6 I restriction enzyme, in 30µl reactions. Digestion assays were incubated for 
12 hours at 37 0C.  PCR amplicon and restriction digests were analyzed by electrophoresis on 
a  2%  ethidium  bromide-stained  agarose  gel  and  visualized  under  UV  transillumination. 
Restriction digests were loaded in 15 µl volumes per lane while undigested product was run in 
5µ loading volumes. Band sizes were measured using Syngene gel imaging analysis software.
3.10.7 Molecular Genotyping of isolates using MSP1&2 and Glurp
Primers and PCR protocols were followed as previously described by Snounou et al.  (1999) 
for  family  specific  allele  analysis  of  msp-1  (block  2)  and  msp-2  (block  3).  For  PCR 
amplification, the primers for each of the families in msp-1 and msp-2 are as shown in Table 
3.1. and described by Snounou et al., 2007. PCR condition consisted of an initial denaturation 
step (5 min at 95°C) and 35 cycles of 30s at 95°C, 72°C for 30 s, and 72°C for 5 min and a 
final elongation at 72°C for 5min.
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Polymerase Chain Reaction (PCR) amplification was performed on thermal cycler (Perkin 
Elmer 9700/2400, UK) in a final volume of 20μl. The PCR products were visualized by UV 
transillumination  at  302nm  on  gel  documentation  system  (Syngenta,  USA)  after 
electrophoresis on 2% agarose gel (Promega/Boehringer) using 0.5 × TBE buffer at 80–100 
volts. Allele sizes were calculated using Genetool programme. To understand the identity of 
Nigerian isolates with respect to isolates of other regions, sequence data available in public 
domains  were  downloaded  for  allelic  families  of  msp-1&2  and  details  are  given  below; 
Thailand(K1-M77730,  MAD20-M77722,  R033-AAA29684,  3D7-  U91676),   Vietnam(K1-
AF509651,  MAD20-AF509653&94,  FC27-AF104696,  3D7-AF104693),  Tanzania(K1-
AF061134, FC27-AY532386), Brazil(K1-AF509714, MAD20-AY714585, FC27-DQ115973, 
3D7-AF177389),  China(MAD20-AF251345),  Sudan(MAD20-AF034635),  Iran(MAD20-
AY138509,  R033-AY138507,  FC27-DQ338451),  Indonesia(K1-AF191061,  R033-
AAF18431),  Western  Africa  (R033-PFAMSA1),  Kenya(R033-AAM21583),  Ghana(FC27-
AF329577),  PNG(FC27-AF329579),  Gambia(FC27-U91668,  3D7-  U91665)  and 
Nigeria(3D7-AF148224) (Joshi et al., 2007).
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Table 3.1 PCR Primers for MSP1, MSP2 and Glutamate rich protein
Primer Name Sequence 5’-3’
Glurp GOF TGAATTGAAGATGTTCACACTGGAAC
Glurp GOR GTGGAATTGCTTTTTCTTCAACACTAA
Glurp GNF TGTTCACACTGAACAATTAGATTTAGATCA
Msp 1 F CTAGAAGCTTTAGAAGATGCAGTATTG
Msp 1 R CTTAAATAGTATTCTAATTCAAGTGGATCA
Msp 1F M AAATGAAGGAACAAGTGGAACAGCTGTTAC
Msp 1R M ATCTGAAGGATTTGTACGTCTTGAATT ACC
Msp 1F K AAATGAAGAAGAAATTACTACAAAAGGTGC
Msp 1R K GCTTGCATCAGCTGGAGGGCTTGCACCAGA
Msp 1F R TAAAGGATGGAGCAAATACTCAAGTTGTTG
Msp 1R R CATCTGAAGGATTTGCAGCACCTGGAGATC
Msp 2 F ATGAAGGTAATTAAAACATTG TCTATTATA
Msp 2 R CTTTGTTACCATCGGTACATTCTT
Msp 2F Fc AATACTAAGAGTGTAGGTGCARATGCTCCA
Msp 2R Fc TTTTATTTGGTGCATTGCCAGAACTTGAAC
Msp 2F D AGAAGTATGGCAGAAAGTAAKCCTYCTACT
Msp 2R D GATTGTAATTCGGGGGATTCAGTTTGTTCG
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Statistical Analysis. 
Statistical  analysis  was  performed  using  Stat  View 5.0.1  (SAS  Institute  Inc.,  Cary,  NC). 
Statistical  significance  was  based on  a α level  of  0.05.  The  data/statistical  analysis  for 
significance were done using Microsoft excel, SPSS and HN-NonLin analysis methods. One-
way analysis  of  variances  was  used  to  compare  the  geometric  mean  parasites  density  in 
patients from different age groups. The Student’s t-test was used to compare mean number of 
alleles  of  P.  falciparum  MSP-1,  MSP-2,  and  GLURP.  P  values  <  0.05  was  considered 
significant for all statistical analysis. Data from all the questionnaires were coded, 
entered and analysed using Epi Info 6.04 and SPSS software.
3.11 Questionnaire Administration
Structured Questionnaires were administered to patients, parents of infants and older children. 
The questionnaire seeks to identify the locality, age and sex of the respondents. In addition, 
the patients’  attitude to use of antimalarial  drugs and Insecticide treated mosquito nets or 
other  means of  controlling  man-mosquito contact  as practiced  in  the locality  and malaria 
management practices by the study population were identified. A cross sectional study was 
conducted in the four zones of Ogun State, Southwestern Nigeria.
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CHAPTER FOUR
RESULTS
4.1. Incidence of Malaria in Ogun State, Southwestern Nigeria.
4.1.1Patients Characteristics
A total of 4066 subjects comprising of 1839 males and 2227 females presenting with malaria 
in four different senatorial  districts  of Ogun state were recruited into the study. The total 
number of subjects recruited in Sango-ota, Abekuta, Ijebu-ode and Sagamu were 1120, 1116, 
995 and 835 respectively. The mean age was 19 years (>1 –70) with 93% less than 25 years.   
4.1.2 Incidence of Malaria
The overall incidence of  falciparum malaria as determined by microscopy in the study area 
was 62.7% (2250/4066). The highest incidence was observed in Sango (75.7%) while the 
lowest (48.4%) was observed in Abeokuta (Table 4.2). Table 4.1 shows the incidence of P. 
falciparum infection in Ogun State, Nigeria according to age and sex.   Age group 1-5yrs had 
the highest incidence of infection (70.8) followed by age group <1year (63.9%) while age 
group  6-15years  had  the  lowest  incidence  (52.8).  The  difference  according  to  age  was 
statistically  significant  (p<0.0001).  The  highest  falciparum malaria  mean  parasitaemia  of 
1080p/µl was recorded among the age group 1-5years while age group >40years recorded the 
lowest mean parasitaemia of 800p/µl. Females had a higher incidence of malaria infection of 
51.8% compared to males 48.2% in this study. The difference in the incidence of infection by 
sex was significant (p<0.0001). 
4.2. In Vitro Drug sensitivity Tests
In-Vitro antimalarial drugs and local herbal extracts sensitivity tests were carried out and the 
IC50 and  IC99 for  each  drug was  determined.  Sample  of  HN-NonLinn  software  statistical 
package used for the data analysis is shown in Figure 4.4. Table 4.3 shows the mean IC50 and 
IC99 values for chloroquine, amodiaquine, mefloquine, quinine, sulphadoxine/pyrimethamine 
and artesunate. The IC50 value is defined as the concentration of an antimalarial  drug that 
inhibits 50 % of schizont maturation as compared with the development in drug-free control 
wells.  IC99 gives  a  result  that  closely  approximates  a  reliable  Minimum  Inhibitory 
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Concentration (MIC). The MIC is generally  defined as the lowest drug concentration that 
inhibits  the development of rings to schizonts. Moreover, the  in vitro threshold values for 
antimalarials have been defined statistically as >2 SD above the mean (Pradines et al., 1998). 
IC50 implies  that  50%  of  the  parasite  could  not  mature  to  schizont  stage  at  that  drug 
concentration while IC99 implies that the antimalarial  drugs inhibited 99% of the parasites 
from maturing to schizont stage at that concentration.  
All  the isolates  tested were sensitive to quinine,  mefloquine and artesunate while  in vitro 
resistance was observed to chloroquine, amodiaquine and SP (Table 4.4). Highest percentage 
of resistance to chloroquine (69.8%) was recorded among isolates from Yewa zone while 
highest  percentage  resistance  to  amodiaquine  (30%) was observed in  Ijebu zone.  Highest 
resistance against SP (10%) was recorded in Yewa and Egba zones. A significant positive 
correlation was observed between the responses to artemisinin and mefloquine (P=0.001), 
artemisinin  and  quinine  (P=0.05),  quinine  and  mefloquine  (P= 0.01),  (Table  4.4).  A 
significant  negative  correlation  was  observed  between  the  responses  to  chloroquine  and 
mefloquine (P=0.05). 
4.3 Prevalence of drug resistant molecular markers
Prevalence of established antimalarial drug resistant markers was assayed for in 100 isolates 
collected from the study area. The molecular markers assayed for in the study were  Pfcrt,  
Pfmdr1, PfDhfr, PfDhps and PfATpase6.Table 4.5 shows the overall and zonewise prevalence 
of the molecular markers to various antimalarial drugs in  P. falciparum isolates from Ogun 
state, Nigeria. Sixty percent of the isolates had Pfmdr1 (Y86) resistance gene while 48% had 
Pfcrt (T76) chloroquine resistance gene. None of the isolate had the PfATpase artemisinin 
resistant gene.  Most of the isolates that showed in-vitro resistance to the drugs also harbored 
the genes coding for resistance to the drugs. Plates 4.1 – 4.5 show gel electrophoresis  results 
for the detection of Pfcrt, pfmdr1,dhfr, dhps andATPase6 genes/mutation respectively. 
4.4 In vitro antimalarial activity of herbal extracts
The results of in vitro antimalarial activity of the three herbal extracts tested for antimalarial 
activity are as shown in Table  4.6. Of the selected three herbal extracts, the highest activity 
62
was obtained with extract of Diospyros monbuttensis (IC50 = 32µg/ml) while the lowest was 
obtained from Morinda lucida (IC50 =250 µg/ml).
4.5 Genetic Diversity of P. falciparum
As an estimate of multiclonality of infection, the minimal number  of P. falciparum strains in 
each individual  was determined by assessing the number of alleles of the genes encoding 
MSP-1 and MSP-2 families.  The MSP-1 and MSP-2 alleles were defined by gene family-
specific PCR assays and analysis of the resulting length polymorphisms of the PCR products. 
One  hundred  P.  falciparum  isolates  analyzed  during  the  study 
demonstrated the highly diverse nature of the field isolates in respect of 
msp-1  (block 2) and  msp-2  (central repeat region, block3). All the three 
reported families of MSP-1(K1, MAD20 and RO33) families and two MSP-2 
(FC27 and 3D7) families were observed among the isolates (Plates 4.6 - 
4.10). 
In MSP-1, Proportion of isolates with K1 family was 68% with 4 alleles in 
the range of 100 to 300 base pairs (bp). Proportion of isolates with MAD20 
family was 40% and a total of 3 alleles were observed within 100 to 300 
bp.  RO33  proportion  was  20%  and  the  family  was  observed  to  be 
monomorphic  with  an  allele  size  of  200  bp.  Observed  proportions, 
numbers and size range of alleles among the isolates are given in Table 
4.7.
In MSP-2, the reported families FC27 and 3D7 were observed among the isolates (Table 4.7).  
Proportion of FC27 family was 76% and that of 3D7 was 56%. Proportional prevalence of 
FC27 and 3D7 families  was significantly  different  (χ2 = 16.5,  P=0.002).  Three alleles  of 
FC27 in the range of 300–500 bp and 3 alleles of 3D7 in the range of 450–600 bp were 
observed in the study. Proportion of multiclonal isolates (multiple infection) is given in Table 
4.7  and  multiplicity  of  infection,  MOI  was  estimated  by  dividing  the  total  number  of 
fragments  detected  in  the  individual  system  by  the  number  of  samples  positive  in  the 
particular system (either  MSP-1  or  MSP-2) and 80% of the isolates harbour the genes that 
code for glutamate rich protein with size ranging between 700 and 900.
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The zonewise genetic diversity of P. falciparum  from Ogun State is as shown on Table 4.8. A 
high polymorphism was recorded in all the zones for MSP-1 (block 2) and MSP-2 (central 
repeat region, block 3). Highest genetic polymorphism was recorded among the field isolates 
from Yewa zone.
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4.6 Knowledge and practice on the use of antimalarial drugs
Questionnaires were administered to respondents resident in the study sites who were either 
malaria  patients  or parents/guardians  of malaria  infected children.  The age of respondents 
ranged between 18 and 75 (Table 4.9). A total of 946 questionnaires were administered to 
assess the malaria related knowledge on issues regarding the use of antimalarial drugs and 
malaria management practices. Most of the respondents were students (52.2%). The responses 
of the participants are summarized in table 4.10. About 32.1% of participants have malaria 
attack at least once in 3 months while only 26.3% normally complete their antimalarial drugs. 
The  malaria  management  practices  showed  that  24.6% attend  hospitals,  12.0% use  local 
healers while 25.0% buy antimalarial drugs without prescription by a physician. It was also 
found that  some use more  than  one method in their  management  of  malaria.  Those who 
combined antimalarial drugs with traditional medicine from local healers were found to be 
17.4%, while 1.2% reported doing nothing about malaria. Table 4.10 also shows the methods 
used in preventing mosquito bites by respondents. Only 18% of the sample population used 
Insecticide treated mosquito nets. Majority of the people (42.3%) used only window and door 
nets; 24% of the population used insecticides while 13% do not prevent mosquito bite at all.
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Table 4.1. Incidence of P. falcifarum infection in Ogun State. 
AGE 
(Yrs)
          No of Samples No of Positive Cases Mean 
Parasitaemia 
p/µl
Male Female Total Male
(%)
Female
(%)
Total
(%)
p.-value
< 1   52 56 108 33
(47.8)
36 
(52.2)
69 
(63.9)
900 <0.0001
(χ²=46.863
1-5   300 324 624 193 
(43.7)
249 
(56.3)
442 
(70.8)
1080
6-15   330 412 742 195
(47.4)
197
(50.3)
392 
(52.8)
890
16-25   901 965 1866 639
(60.8)
500
(44.0)
1139 
(61.0)
850
26-40   208 221 429 110
(41.5)
155
(58.5)
265 
(61.8)
990
> 40 100 305 405 60
(24.7)
183
(75.3)
243 
(60.0)
800
Total 
(%)
1839
(45.2)
2227 
(54.8)
4066
(100)
1230
(48.2) 
1320
(51.8)
2550
(62.7)
             918.3
p- value <0.0001  (χ²=24.632)
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Table 4.2: Zonewise Incidence of Malaria in Ogun State
 
Zone No of Samples collected No of Positive Samples Mean 
parasitaemia
Male Female Total Male Female Total
920Ijebu Ode (Ijebu) 455 540 995 315 348 663 
(66.6)
Sango Ota (Yewa) 536 584 1120 412 436 848 
(75.7)
914
Abeokuta (Egba) 502 614 1116 251 289 540 
(48.4)
860
Sagamu (Remo) 346 489 835 252 247 499 
(59.8)
980
Total (%) 1839 
(45.2)
2227 
(54.8)
4066 
(100)
1230 
(48.2)
1320 
(51.8)
2550 
(62.7)
918.3
Table 4.3: In vitro susceptibility of P. falciparum isolates to Antimalarial Drugs
67
Drug IC50 Mean 
(nM/L)
IC99 Mean 
(nM/L)
Resistance Threshold 
(nM/L)
Chloroquine (CQ) 24.4 164.2 > 160
Amodiaquine (AQ) 6.3 32.4 > 80
Artesunate (AS) 3.2 7.8 > 10.5
Mefloquine (MQ) 42.1 60.8 > 64.0
Sulphadoxine  – 
Pyrimethamine
55.0
0.7
200
2.5
>300
>4.0
Quinine 60.3 298.6 >300
Table  4.4:  Zonewise  resistance  pattern  of  P.  falciparum  to  antimalarial 
drugs
Origin No. Isolates CQ res AQ res AS res MQ res SP res (%) Q res 
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Cultured (%) (%) (%) (%) (%)
Ijebu-Ode 
(Ijebu)
20 9
 (45)
6 (30) 0 (0) 0 (0) 1 (5) 0 (0)
Sango  Ota 
(Yewa)
43 30 
(69.8)
4 
(9.3)
0 (0) 0 (0) 2 (10) 0 (0)
Abeokuta 
(Egba)
25 5 
(20)
1 (4) 0 (0) 0 (0) 2 (10) 0 (0)
Sagamu 
(Remo)
12 7 
(58.3)
2 
(16.7)
0 (0) 0 (0) 0 (0) 0 (0)
Total 100 51 
(51)
13 
(13)
0 (0) 0 (0) 5 (5) 0 (0)
CQ-Chloroquine; AQ-Amodiaquine; AS-Artesunate; MQ-Mefloquine;
SP-Sulphadoxine/Pyrimethamine; Q-Quinine; res-resistance
 
Table 4.5: Zonewise Prevalence of molecular markers of resistance to antimalarial drugs 
in P.  falciparum from Ogun State, Southwestern Nigeria. 
Zone No.  of             Prevalence of resistance genes
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Isolates pfcrtK76T 
(%)
Pfmdr1Y86N 
(%)
PfdhfrS108N 
(%)
pfdhpsK540E
(%)
pfATPaseS769N
(%)
Ijebu 20 9 (45) 10 (50) 3 (15) 0 (0) 0 (0)
Yewa 43 28 (65.1) 30(69.8) 4 (9.3) 1 (2.3) 0 (0)
Egba 25 5 (20.0) 12 (48) 4 (16) 1 (4) 0 (0)
Remo 12 6 (50.0) 8 (66.7) 1 (8.3) 0 (0) 0 (0)
Total 100 48 (48) 60 (60) 12 (12.0) 2 (2) 0 (0)
Table 4.6 In vitro susceptibility of P. falciparum isolates to Local Antimalarial Herbs
Herbal Drug
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Momordica charantia                                    125.0
(Ejirin)
Morinda lucida (Oruwo)                               250.0
Diospyros monbuttensis                                  32.0
(Eegun eja)
Table 4.7: Genetic diversity of Plasmodium falciparum isolates from Ogun State, 
Southwestern Nigeria
Families         No. positive 
by PCR (%)    
No. of 
distinct 
alleles
   Sizes of 
alleles (bp) MOI
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MSP-1                      
K1 
68(68)
MAD20                       40(40)
RO33 
20(20)
MSP-2
3D7 
76(76)
FC27 
56(56)
4
3
1
3
3
100-300
100-300
200
450-600
300-500
1.1
1.2
GLURP
80 (80)
5 700-900 1.3
* bp _ basepairs; MSP _ merozoite surface protein; GLURP _ glutamate-rich 
protein.
MOI Multiplicity of Infection
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Table 4.8: Zonewise Genetic Diversity of P. falciparum from Ogun State, Southwestern 
Nigeria
Legend:  MSP 1-  Merozoite  surface  protein  1;  MSP 2-  Merozoite  surface  protein  2 
Glurp- Glutamate rich protein.
Prediposing Factors to Antimalarial Drug resistance
Table 4.9:  Age Range of respondents
Zone No  of 
Isolates
                          MSP 1 MSP 2
Glurp 
(%)
K1 (%) MAD20 
(%)
RO33 
(%)
3D7 (%) FC27 
(%)
Ijebu 20 14 (20.6) 9 (22.5) 6 (30) 16 (21.1) 13 (23.2) 16 (20)
Yewa 43 31 (45.6) 21 (52.5) 8 (40) 38 (50) 18 (32.1) 33 (41.3)
Egba 25 15 (22.1) 7 (17.5) 4 (20) 12 (15.8) 18 (32.1) 21 (26.3)
Remo 12 8 (11.8) 3 (7.5) 2 (10) 10 (13.2) 7 (12.5) 10 (12.5)
Total 100 68 (100) 40 (100) 20 (100) 76 (100) 56 (100) 80 (100)
Age range (Years) Frequency (%)
18-25 527 55.7
26-35 231 24.4
36-45 126 13.3
>45 62 6.6
Total                                                  946 10073
Table 4.10: Knowledge on prevention and control of malaria among respondents
Variable N = 946 %
Episode of Malaria Infection
         Once in a month
         Once in three months
         Twice in a year
         Once in a year
         Others          
312
304
144
141
45
33
32.1
15.2
14.9
4.8
Reasons for stopping drug usage
        When I feel okay/cured
        Price of drugs
        When I complete dosage
        Anytime I like
340
236
249
121 
35.9
24.9
26.3
12.8
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Antimalarial used as prophylaxis
       Quinolines
       Sulphonamides
       Artesunate
       Artemisinin Combination Therapies
       Local herbs
       Others
385
316
74
30
142
2
40.7
33.5
7.9
3.2
15.1
0.3
Mosquito bite Preventive methods used
       Insecticide treated Bed nets
       Insecticides
       Mosquito repellant cream
       Window nets
       None
170
227
26
400
123
18
24
2.7
42.3
13
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Figure 4.1. Sample of HN-NonLinn Software Statistical Package for the analysis of in-vitro 
drug sensitivity data for Plasmodium species  
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AQ,
13AQ,
87
CQ, 51CQ, 49
Res
Res
Sens
Fig 4.2 Cross Resistance between Chloroquine and Amodiaquine, n=64. The figure shows 
a cross resistance between chloroquine and amodiaquine. All the P. falciparum isolates that 
showed resistance to amodiaquine were resistant to chloroquine.
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Plate 4.1: DNA bands of wild type and mutated P.
falciparum chloroquine resistance genes
M
265bp
132bp
Plate  4.1:  Gel  Electrophoresis  showing  the  DNA bands  of  wild  type  and  mutated  Pfcrt  
(K76T) gene after digestion with APO I enzyme. The undigested DNA fragments (265 bp) are 
the resistance genes while the digested DNA fragments with 132 bp are the sensitive strains as 
shown on plates. 
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Plate 4.2: P. falciparum Multidrug Resistance 
Genes showing the wild type and mutated genes
165bp
325bp
M
Plate 4.2 shows the Pfmdr1 (Y86N) genes on gel electrophoresis after digestion with Afl III 
enzyme. The isolates with DNA fragments of size 325bp are the wild type i.e. sensitive strains 
while  the mutated  strains  were cut  by the  restriction  enzyme to 165bp. M respresent  the 
molecular size marker
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Plate 4.3: DNA band of Dihydrofolate reductase gene 
(DHFR 108)
322bp
708bp
M
Plate 4.3 shows the wild type and mutated genes of DHFR 108 for Sulphadoxine resistance.
The wild type gene has a band size of 708bp while the mutated gene has a band size of 322bp.
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Plate 4.4: DNA band of Di hydropteroate synthase gene (DHPS 540)
M
441bp
756bp
M M
Plate 4.4 shows the DNA band of wild type and mutated genes of Dihydropteroate synthase 
(DHPS 540). The band size of wild type is 756bp while that of the mutated gene is 441bp
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Plate 4.5: DNA band of wild type Pf ATPase6
M M
The band size of the genes coding for pfATPase6 of between 430bp and 432bp is as shown on 
plate 4.5. There was no digestion which means that none of the isolates harbour resistance 
genes coding for artemisinin resistance.
82
 M
M
180bp
300bp 200bp
Plate 4.6: DNA bands of P. falciparum MSP1 MAD20 on Gel
Legend: M-marker; bp-base pair; 180bp, 200bp 300bp - different alleles for MSP1 MAD family
The DNA bands of genes coding for  P. falciparum Merozoite Surface Proteins 1 (MSP1) 
MAD and K and RO33 are as shown on Plates 4.6, 4.7 and 4.8 respectively. The band size for 
MAD is between 180 and 300 basepairs (bp) while that of K is 100-300bp.  For RO33 the 
band size in the range of 200 bp. M is the molecular size marker  
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Plate 4.7: DNA bands of P. falciparum
MSP1 K1 on Gel
M
M
100bp
200bp
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M200bp 200bp
Plate 4.8: DNA bands of P. falciparum MSP1 RO33 on Gel
Legend: M-Molecular marker; bp-basepairs; 200bp-allelic size
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Plate 4.9: DNA bands of P. falciparum MSP2  
3D7 on gel
M
M
500bp
400bp
600bp
500bp
Legend: M-molecular marker; bp-basepairs; 400-600-allelic sizes
The DNA bands of genes coding for  P. falciparum Merozoite Surface Proteins 2 (MSP-2) 
3D7 and FC27 are as shown on Plates 4.9 and 4.10 respectively. The band size for 3D7 is  
between 400 and 600bp while that of FC27 is 400-500bp. M is the molecular size marker.
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Plate 4.10: DNA bands of P. falciparum
Merozoite Surface Protein 2  FC27 on gel
M
400bp
500bp
Legend: M-Marker; 400bp, 500bp- allelic sizes
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Plate 4.11: DNA band of P. falciparum Glutarmate rich protein 
900bp800bp
M
700bp
Legend: M-molecular marker; bp-basepairs; 700-900bp-allelic sizes
The DNA bands of genes coding for P. falciparum Glutamate Proteins are as shown on Plate 
4.11. The band size is between 700 and 900 basepairs (bp).is 400-500bp.  M is the molecular 
size marker  
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CHAPTER FIVE
DISCUSSION
Plasmodium falciparum which  causes  the  most  serious  type  of  malaria  especially  in  sub 
Saharan Africa was studied in this research work among the people of Ogun State Nigeria. 
Malaria is the most prevalent tropical disease in the world today and in sub-Saharan Africa, it  
is  ranked  among  the  most  frequent  causes  of  morbidity  and  mortality  especially  among 
children and is often the leading identifiable cause (Greenwood et al., 2005). Four thousand 
and sixty six (4066) subjects were included in the study on the incidence of  P. falciparum 
infection in Ogun state, South Western Nigeria. Two thousand, five hundred and fifty (62.7%) 
were positive for  falciparum malaria with an average parasitaemia of 918. This result is in 
agreement with earlier observations that Nigeria is known for high prevalence of malaria and 
it  is  a  leading  cause  of  morbidity  and  mortality  in  the  country  (Sowunmi  et  al.,  2004; 
Ademowo et al., 2006).  The high incidence rate of falciparum malaria in the selected study 
site  is  similar  to  the  results  of  earlier  studies  in  other  parts  of  the  country  and  other 
neighboring countries. Adefioye et al. (2007) and Marielle et al. (2003) recorded a prevalence 
rate of 72% and 70% among pregnant women in Oyo state, Nigeria and Gabon respectively.  
A prevalence rate of 76% was also reported by Aribodor  et al.  (2003) in Anambra State, 
South East Nigeria.
The result  of  this  study was  differs  from that  of  Uko  et  al.  (1998) who recorded  a  low 
prevalence rate of (6.8%). This may be due to the fact that the study was carried out during 
dry season alone when infection rate was low. Chanda  et al.,  (2009) reported a very low 
incidence of 0.7% among children less than five years attending a local  health  facility  in 
Zambia. In this study, 63.9% of children below one year and 70.8% of the children 1-5 years 
were positive for falciparum malaria and highest parasitaemia was also observed in this age 
group. This was followed by age range 16-25years with a prevalence of 52.8%. This findings 
was in agreement with those of Aribodor et al. (2003) who also observed a high prevalence 
rate among age group 10-19 years followed by age group 20-29 years old. In highly endemic 
malarious area where semi-immune adults usually have substantially acquired resistance to 
local strains of plasmodia, the prevalence of clinical malaria is higher and its severity greater 
in pregnant women, children and young adults. The high prevalence rate in the study area 
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could result to cerebral malaria in children, maternal anaemia and low birth weight and death 
as  reported  by  other  workers  (Mockenhaupt  et  al.,  2000;  WHO, 2003).  This  is  probably 
because they are more exposed to malaria parasite due to bad environmental conditions and 
their life styles
In-vitro method was used in  this  study to determine  the quantitative  drug response of  P. 
falciparum to  various  antimalarial  drugs  that  are  in  use  in  Nigeria.  Resistance  to 
antimalarial  drugs  can  be  assessed  in  vitro  by  the  degree  of  parasite  growth 
inhibition exerted by particular antimalarial drugs (Basco and Ringwald, 2007; Oduola et al., 
1993).  In  any  therapeutic  strategy,  establishment  of  the  baseline  sensitivity  of  local  P. 
falciparum  isolates to commonly prescribed drugs that are still  effective in some endemic 
areas and new drugs that are not yet widely available in a country but might be employed in 
the near future (e.g. artemisinin derivatives) is important. The  in vitro assay is particularly 
useful for fulfilling this function as it provides an objective, quantitative measure.
In-vitro resistance  against  chloroquine,  amodiaquine  and 
sulphadoxine/pyrimethamine was observed among Nigerian isolates of  P. 
falciparum tested. In the cross sectional study, an IC50 of 24.4nM/L and IC99 
of  164.2nM/L  was  recorded  for  chloroquine  respectively.  These  results 
were similar to earlier findings of  Wongsrichanalai  et al. (2000) where a high  IC50 
was also recorded.  Resistance threshold  of  isolates against chloroquine 
and  amodiaquine  were  above  160nM/L  and  80nM/L  respectively  which 
denoted resistance against the drugs. Moreover, resistance threshold of 
isolates  against  Sulphadoxine  and  pyrimethamine  were  300nM/L  and 
4.0nM/L respectively. All the isolates tested against mefloquine, quinine 
and  artesunate  in  this  study  were  sensitive  to  the  drugs.  The  IC50  of 
42.1nM/L observed in mefloquine in this study is slightly higher than that 
recorded  in  earlier  findings  of  Reber-Liske  (1983)  where  IC50  of  39.7nM/L  was 
observed. The sensitivity ranges observed in the current study was also within the range for 
sensitivity  of  isolates  to  the  drug  (WHO,  2001).  In-vivo resistance  against  chloroquine, 
amodiaquine, mefloquine and sulphadoxine /pyrimethamine has been reported by researchers 
in  Nigeria  (Happi  et  al.,  2004;  Ogunfowokan  et  al.,  2009).  The  in  vivo  response  of  P. 
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falciparum  to  antimalarial  drugs  is  modulated  by a  number of  factors.  These include  the 
pharmacokinetic properties of antimalarial drugs, innate and acquired immunity in the patient, 
as well as the complexity of infections in high transmission areas (Happi et al., 2004). Several 
of  these  factors  may  contribute  to  the  range  of  variations  in  the  clinical  expression  of 
chloroquine resistance and in vitro resistance patterns.
All  the  isolates  tested  in  vitro against  artemisinin  were  sensitive  to  the  drug.  However 
treatment failures have been observed by other workers from Southwestern Nigeria during in  
vivo studies (Happi  et al., 2004). Bioavailability of the drugs in the system amongst other 
factors  has  been  attributed  to  treatment  failures  (Ibrahim  et  al.,  2007).  Although 
dihydroartemisinin is the active ingredient in the artemisinin based drugs. Artesunate® which 
contains artemisinin was used for the in vitro drug testing in this study. This is because it has 
been reported that dihydroartemisinin is unstable on drug plates and that artemisinin is the 
most appropriate drug for in vitro drug assays due to its stability in pre-dosed plates (Tanariya 
et al., 2000).
High  resistance  against  chloroquine  and  amodiaquine  were  observed  among  the  isolates 
collected from Yewa and Ijebu zones while SP resistance was not observed in isolates from 
Remo zone. There was cross resistance between chloroquine and amodiaquine as some of the 
isolates that showed resistance to chloroquine also showed resistance to amodiaquine in all 
the zones. Cross-resistance between chloroquine and amodiaquine has been reported both in  
vitro  and  in vivo. Pradines  et al. (1999) have observed cross resistance of chloroquine and 
amodiaquine in earlier studies. It has also been observed that parasites may quickly develop 
resistance  to  amodiaquine  in  areas  where  extensive  chloroquine  resistance  has  been 
documented (Winkler et al., 1994). 
Antimalarial drug resistance is now generally acknowledged to be one of the greatest threats 
to our ability to “Roll Back Malaria (Molta, 1995; Federal Ministry of Health 2004). The 
situation  is  worsening,  with  the  geographic  spread  of  resistance  widening  to  previously 
unaffected  areas  and  a  remorseless  increase  both  in  the  prevalence  and  degree  of  drug 
resistance.  Resistance to chloroquine and sulfadoxine-pyrimethamine (SP) is widespread in 
Asia and South America and is spreading in Africa. This is evidenced in the results of this 
study as there was  in vitro resistance against chloroquine. The burden of disease caused by 
91
malaria and its consequences has been documented in terms of childhood mortality, anemia, 
maternal and infant morbidity and mortality, neurologic disability, and economic and social 
costs.  The  burden caused specifically  by  antimalarial  drug resistance  is  more  difficult  to 
quantify. Resistance against chloroquine was observed in all the four zones where this present 
study was carried out. 
There is an increasing acceptance that the ideal approach to antimalarial treatment is the use of 
combination of two or more drugs,  rather  than a  single antimalarial  drug, preferably with 
artemisinin derivative as one of the drugs (WHO, 2001; Ashley et al., 2007). Amodiaquine in 
combination with artesunate has been introduced as first-line treatment of malaria to replace 
chloroquine in Nigeria and other malaria-endemic countries of Africa (Sodiomon et al., 2009). 
Although the  role  of  artesunate  in  this  combination  is  to  prevent  the  development  of 
amodiaquine  resistance,  parasites  may quickly  develop resistance  to amodiaquine  in areas 
where extensive  chloroquine  resistance  has  been documented.  In addition,  little  is  known 
about the mechanism or epidemiology of amodiaquine resistance. Resistant parasites may then 
likely  recrudesce under  the selective force of  the second drug in  the combination  and be 
transmitted to  mosquitoes  (WHO,  2003).Therefore,  we  cannot  rule  out  the  possibility of 
increasing selection of amodiaquine-resistant parasites with the increasing use of amodiaquine 
in combination with artesunate in Nigeria. 
Reduced in-vitro susceptibility is not synonymous with diminished therapeutic effectiveness, 
but it is the probable first step of an alarming cascade and definitely pleads for increased 
vigilance and a coordinated and rapid deployment of drug combinations. A previous study in 
Nigeria  assessed  the  quality  of  drugs  from  retail  outlets  and  pharmacies  and  attributed 
problems  to  a  lack  of  quality  control  in  manufacture  and  degradation  during  storage 
(Onwujekwe et al., 2009). A major problem with the treatment of malaria is the high level of 
treatment failures resulting in the large part from the high prevalence of counterfeit  drugs 
bought by the patients   (Hall  et al., 2006; Newton  et al., 2006; Onwujekwe  et al., 2009). 
Anti- malarials are among the most widely consumed drugs in tropical countries that have 
been particularly targeted by counterfeiters and of the anti-malarial drugs used in the world 
today
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Developing  countries,  where  malaria  is  one  of the  most  prevalent diseases,  still  rely  on 
traditional  medicine  as  a  source  for the  treatment  of this  disease.  While  synthetic 
pharmaceutical agents continue to dominate research, increasing attention has been directed to 
natural products (Alshwash et al., 2007). The success of artemisinin, isolated from Artemisia  
annua, and its derivatives for the treatment  of resistant malaria has focused attention on plants 
as a source of antimalarial drugs (Tan et al., 1998). In this study, three crude organic extracts 
obtained from medicinal plants used in Nigerian folk medicine for the treatment of fever and 
malaria were tested in vitro against P. falciparum. The most active extract was obtained from 
Diospyros  monbuttensis that  showed  appreciable  inhibition  to  the  parasites  at  all  the 
concentrations used and an IC50 of 32μg/L in the study.  Diospyros monbuttensis,  which is 
locally used for the treatment of fevers, headaches and stomach disorders, (Awe and Makinde, 
1997; Azas et al., 2002) has not been widely studied. This study represents the first conducted 
for antimalarial activity of crude extracts of Diospyros monbuttensis. The results confirm that 
those plants which are used in traditional medicine against malaria may possess in vitro and 
significant antimalarial potential and justify their use in traditional medicine. This observation 
suggests  that  the  active  constituents in  the  extract  may  be  cytotoxic  for  P.  falciparum 
trophozoites, thereby inhibiting their development to the schizont stage. 
However, in vivo studies on these medicinal plants are necessary and should seek  to determine 
toxicity of the active constituents, their side effects, serum-attainable levels, pharmacokinetic 
properties and diffusion in different body sites. Additional pharmacokinetic  investigations are 
therefore  advisable  to identify  host-related factors,  such  as  poor  absorption,  accelerated 
gastrointestinal passage  of the test drug, or metabolic peculiarities  of some patients, which 
might lead  to a faster-than-normal inactivation or elimination  of the test drug (Azas  et  al., 
2002).  The  use  of  herbs  by  some local  people  proved 100% sensitive  to  P.   falciparum 
(Merlin, 2004; Ogbonna, et al., 2008).
An IC50 observed for  Momordica charantia  in this study was 125μg/L. These observations 
suggest that the active constituents in the extract might also be cytotoxic for  P. falciparum 
trophozoites, thereby  inhibiting  their  development  to the  schizont  stage.  The  antimalarial 
activity of Momordica charantia has been previously reported (Alshwash et al., 2007). They 
found that the aqueous extract of. M. charantia leaves showed IC50 values less than 100 µg/ml 
which is  in agreement with the observations  in  this  study; the methanolic  extract  showed 
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moderate activity with IC50 =125 µg/ml. Morinda lucida also exhibited antimalarial activities 
in this study. The IC50  of 250μg/L observed in this study is comparable with other studies. 
Also for  M. lucida,  dose-dependent inhibitory outcomes were marked. Awe and Makinde, 
(1997) reported the dose-dependent and seasonal variation in the activity of M. lucida using 
both in vitro and in vivo techniques.  M. lucida was reported to contain anthraquinones which 
showed  in  vitro activity  against  P.  falciparum and  also  possesses  antifungal  properties. 
Morinda lucida  is used locally in the treatment of yellow fever and jaundice (Guido  et al., 
1995).
One of the factors to be considered in the prophylaxis, treatment, and control of Plasmodium 
falciparum malaria is the resistance of parasite strains that may arise against virtually every 
drug available. Identification of  Pfcrt  as the central determinant of chloroquine-resistant  P. 
falciparum malaria provides a molecular marker that can be used for surveillance of resistance 
and to evaluate drug treatment and prophylaxis policies. The present results further support 
this  role  of  the  Pfcrt  gene.  In the current  study,  100  P. falciparum  clinical  isolates  were 
collected during 2007-2008 and 49 (49%) of these samples were found to be chloroquine-
sensitive and  51  (51%)  chloroquine-resistant  using  the  WHO  in  vitro microtest method. 
Amplification products from all the chloroquine-sensitive  samples carried the codon for Pfcrt 
76K. Out of the 51 samples that were chloroquine-resistant by in vitro testing, 48 were found 
to  carry  the  76T  codon,  5  were  found  to  contain  mixed  76T/76K  codons,  and  3  were 
discordantly found to contain the 76K codon. The results  of work showed that  there is  a 
positive correlation between in-vitro resistance pattern of isolates and prevalence of molecular 
markers of resistance in the four zones. This finding corroborates with earlier findings where 
molecular  markers  of  resistance  were  found in  samples  that  gave  in  vivo resistance/drug 
failure (Djimde et al., 2001; Chen et al., 2001; Happi et al., 2004).
The high prevalence  of  mutations  at  codons 76T,  that  code for  chloroquine  resistance  in 
Nigerian P. falciparum isolates suggests that the population of P. falciparum that circulates in 
South-Western Nigeria has been selected by the long use of CQ. The overall picture emerging 
from this study is that resistance to this drug is abundant in south- Western Nigeria, and this 
finding strongly supports withdrawal of CQ as the first-line drug for treatment of falciparum 
malaria in Nigeria. This observation also supports the view that the  Pfcrt  polymorphism at 
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position 76 is in fact a significant factor of CQ resistance, as shown in previous studies from 
Cameroon (Basco and Ringwald, 2001.), Mali (Djimde et al., 2001), Mozambique (Mayor et  
al., 2001),  Nigeria  (Adagu  and  Warhurst,  2001),  Sudan  (Babiker  et  al.,  2001),  Uganda 
(Kyosiimire-Lugemwa et  al.,  2002),  Madagascar  (Ariey  et  al.,  2002), Laos  (Labbe  et  al., 
2001), Papua New Guinea (Maguire et al., 2001), and Thailand (Chen et al., 2001; Jürgen and 
Christian, 2003). CQ resistance has been attributed to a single mutation at codon 76 in the 
Pfcrt gene (Djimde et al., 2001; Basco and Ringwald, 2001). 
It has been observed that the Pfcrt K76 and the Pfmdr1 Y86 alleles are closely associated in 
chloroquine resistant strains (Adagu and Warhurst, 1999). A similar observation was made in 
this study as all isolates carrying Pfcrt mutated allele were also positive for Pfmdr1 mutated 
allele. However, studies comparing the associations of the Pfmdr 1 variant and the Pfcrt K76 
variant have shown that the impact of the pfcrt gene was stronger than that of the pfmdr gene 
(Djimde et al., 2001; Dorsey et al., 2001; Ojurongbe et al., 2007). It has been suggested that 
the degree of chloroquine resistance is further modulated by factors linked to genes other than 
Pfcrt or Pfmdr (Chen et al., 2001). 
Consistent with other studies, one can assume that the prevalence of Pfcrt T76 is a function of 
the actual chloroquine level, age of the patient, and also influenced by acquired immunity and 
natural resistance factors of the host (Wellems and Plowe 2001). Furthermore, one can assume 
that chloroquine intake contributes essentially to the selection of the Pfcrt T76 allele. Based 
on these observations, chloroquine appears to have an extended influence on the distribution 
of the  Pfcrt polymorphism in an isolate.  Thus, sub-therapeutic blood levels of chloroquine 
promote the emergence of drug resistance by direct selection.
Molecular  methods that detect  genetic  markers of drug resistance are potentially  powerful 
tools for tracking drug-resistant malaria. In this study, the combination of  Pfcrt and  Pfmdr1 
mutations in isolates associated with  in vitro amodiaquine resistance was observed. Mutant 
PfcrtT76 and Pfmdr1Y86 alleles were observed in 48% and 60% of the samples, respectively. 
A previous study in Sudan (Babiker  et al.,  2001) found that the mutant  PfcrtT76 allele is 
associated with amodiaquine treatment failure. The high prevalence of the mutant  PfcrtT76 
allele (48%) and Pfmdr1 allele (60%) observed in Ogun State, Nigeria confirms recent reports 
of the high prevalence rate of this alleles in parasites obtained from similar studies (Happi et  
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al.,  2006) and is  also consistent  with rates  ranging  from 60% to  100% reported  in  other 
malaria-endemic  regions  (Maguire  et  al.,  2001;  Basco and Ringwald,  2001; Djimde  et  al 
2001). The non-significant selection of the mutant  PfcrtT76 by amodiaquine may be due to 
the high prevalence of this allele in the P. falciparum population from South Western Nigeria. 
Selection of  Pfmdr1Y86 by amodiaquine has also been reported previously in the Gambia 
(Happi  et  al.,  2003).  Although  the  importance  of  point  mutations  in  Pfcrt in  producing 
chloroquine resistance is beyond dispute (Basco and Ringwald, 2001; Maguire  et al., 2001; 
Chen et al., 2001) recent transfection studies of Pfcrt have shown that isolates expressing the 
mutant PfcrtT76 allele  retain  sensitivity  to  amodiaquine  while  showing  a  reduced 
susceptibility to monodesethyl amodiaquine, the active metabolite of amodiaquine (Happi et  
al., 2003). The selection of the mutant  PfcrtT76 and Pfmdr1Y86 alleles indicates the primary 
involvement of these two genes in the mediation of amodiaquine resistance. Thus, similar to 
chloroquine  resistance,  amodiaquine  resistance in  P. falciparum may depend primarily  on 
mutation(s) in Pfcrt and additional mutations in Pfmdr1 or other Plasmodium genes may also 
have significant roles in increasing resistance to the drug. 
The combination  of  pfcrtT76 and  pfmdr1Y86 mutations  was associated with  amodiaquine 
treatment  failure.  These  two  alleles  have  been  shown to  be  in  linkage  disequilibrium  in 
chloroquine-resistant isolates of P. falciparum from The Gambia and Nigeria (Happi  et al., 
2003). The similarity in the chemical structures of chloroquine and amodiaquine and their 
possible likely common mode of action suggests that the molecular basis of resistance to these 
two drugs may be similar. 
Resistance against Sulphadoxine and Pyrimethamine was observed in this study. Among the 
isolates analyzed for resistance markers,  PfdhfrS108N and  PfdhpsK540E genes coding for 
Pyrimethamine and Sulphadoxine respectively were detected. It has been earlier observed that 
Resistance to pyrimethamine is primarily conferred by a non synonymous point mutation at 
codon  108  and  is  consecutively  enhanced  by  mutations  at  codons  51  and  59  of  the  P. 
falciparum pfdhfr gene located on chromosome 4 (Bruce-Chwatt, 1985; Kublin et al., 2002). 
The enzyme is part of the folate pathway and, thus, of DNA replication. In this study genes 
that code for sulphadoxine and pyrimethamine resistance were detected among the isolates 
screened  for  markers  of  resistance  against  these  drugs.  PfdhfrS108N  and  PfdhpsK540E 
alleles were detected in 12 and 2 isolates respectively.
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On the  basis  of  evolutionary  theories,  biological  disadvantages  are  expected  for  parasites 
carrying resistance-mediating mutations in the absence of drug pressure. The fitness deficit 
conferred by the  PfdhfrS108N mutation in the absence of pyrimethamine use is considered 
quite low. Enduring resistance in the absence of strong drug pressure implies that the expected 
decline  in  the  prevalence  of  resistant  parasites  is  balanced  by  mechanisms  that  confer 
biological advantages with regard to survival fitness, replication and transmission probability, 
invasion, reproduction, and vector properties that favor transmission. As Sub-Saharan African 
countries are confronted with the rapid emergence of resistance against virtually every drug 
that  is  used  for  the  treatment  of  P.  falciparum,  malaria  drug  pressure  is  considered  to 
essentially promote the emergence of SP resistance, which is now widespread in East Africa, 
but also well recognized in West Africa. 
Selection for the Ser to Asn substitution at codon 108 of the Pfdhfr gene has been shown to be 
linked to parasite survival after treatment with pyrimethamine -containing regimens (Plowe et  
al., 1998;  Marks  et  al.,  2005).  Accordingly,  the  high  frequencies  of  resistant  parasite 
populations  have  been  attributed  to  increased  pyrimethamine  consumption  (Marks  et  al., 
2005).  An  Asp  to  Ile  substitution  at  codon  Pfdhfr51  (PfdhfrN51I)  and/or  a  Cys  to  Arg 
exchange at codon pfdhfr59 (pfdhfrC59R) appears to enhance pyrimethamine resistance if one 
or  both  of  these  occur  concurrently  with  PfdhfrS108N.  PfdhfrS108N-N51I-C59R  is  the 
combination  of  mutations  most  strongly  associated  with  pyrimethamine  resistance.  Point 
mutations  at  codons  437  and  540  of  the  Pfdhps  gene  located  on chromosome  8  of  P. 
falciparum  are  considered  responsible  for  sulphadoxine  resistance.  Pfdhps  encodes  a  key 
enzyme in the folate pathway, as does  Pfdhfr. The Ala to Gly substitution at position 437 
(PfdhpsA437G) is, in general, the first mutation to occur. In Africa this is followed by the Lys 
to Glu substitution at position 540 (PfdhpsK540E), which confers higher levels of resistance. 
It was recently shown that the presence of the three Pfdhfr mutations combined with the two 
Pfdhps mutations (quintuple mutation) is strongly associated with SP resistance (Marks et al., 
2005).
Geographical clustering was reported for chloroquine-resistant  Pfcrt (Wootton  et al., 2002) 
and anti folate resistant Pfdhfr and Pfdhps haplotypes (Cortese et al., 2003), indicating distinct 
ancestral  selection  events  in  different  areas.  One important  aspect  in  the  possible  setting 
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leading to drug resistant parasites in Western Nigeria is the genetic background of the local 
parasite population. Multidrug-resistant  P falciparum is common, with a high rate of  Pfcrt,  
Pfmdr1, Pfdhfr and Pfdhps resistance haplotypes. Thus, selection pressures were exerted on a 
heavily  mutated  genetic  background.  The  several  PfATPase6  haplotypes  harbouring  the 
S769N mutation indicate that selections of such mutants are therefore not impossible in the 
nearest  future.  As  chloroquine  and  SP  are  replaced  by  more  effective  artemisinin-based 
combination therapies  (ACTs), strategies  for monitoring  (and, if  possible,  deterring)  drug-
resistant malaria must be updated and optimized.  In vitro methods for measuring resistance 
will be critical for confirming and characterizing resistance to ACTs. Molecular markers are 
useful for tracking the emergence and dissemination of resistance and guiding treatment policy 
where resistance is low or moderate.
One hundred samples that were positive for P. falciparum by microscopy were subjected to 
PCR genotyping for estimating prevalence of the PfATPase codon S769N mutation. All the 
100 (100%) isolates carried the artemisinin sensitive wild type allele, S769. This observation 
is  similar  to  the  ones  observed  in  several  African  countries  where  artemisinin  and  its 
derivatives are used as first line of treatment of uncomplicated malaria (Basco and Ringwald, 
2001; Djimde  et al., 2001; Mayor  et al., 2001; Adagu and Warhurst, 2001; Babiker  et al., 
2001;  Kyosiimire-Lugemwa et  al.,  2002). However  Artemisinin  resistant  genes have been 
detected by some workers especially in South Asia (Labbe et al., 2001; Maguire et al., 2001; 
Chen  et  al.,  2001;  Jürgen and  Christian,  2003).  Artemisinin  derivatives  are  an  essential 
component of treatment against multidrug-resistant  falciparum malaria. The genes that code 
for artemisinin resistance was not detected in any of the isolates screened for antimalarial 
resistance genes. Widespread multidrug-resistant falciparum malaria led WHO to recommend 
combination drug therapy as first-line treatment, with formulations containing an artemisinin 
compound as policy standard. Artemisinin and its derivatives are the most potent and rapidly 
acting antimalarials. However, artemisinin resistance has been reported in murine models of 
malaria (Ferrer-Rodiriguez et al., 2004). Diligent surveillance is needed to monitor continued 
susceptibility to artemisinin derivatives in endemic areas.
Numerous studies have demonstrated that children under five years and pregnant women are 
at a higher risk of suffering from clinical malaria (Sachs and Malaney, 2002; Greenwood et  
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al.,  2005;  Adefioye  et.  al., 2007;  Sotimehin  et  al.,  2008),  and drug prevention has  been 
advocated for years, using either weekly or monthly prophylaxis or, more recently in several 
countries, intermittent presumptive treatment, IPT (Cot and Deloron, 2003). At a time, many 
countries in the Sub Saharan region recommended a weekly chloroquine prophylaxis for each 
pregnant woman from the beginning of pregnancy to delivery. One possible drawback of such 
increased drug consumption is an increased drug pressure that may lead to the selection of 
drug-resistant parasites. There is some evidence in favor of this hypothesis. For instance, in 
countries where Artemisinin resistance has been discovered, all resistant isolates came from 
areas with uncontrolled use of artemisinin derivatives (Ronan et al., 2005)
There  is  little  existing  knowledge  about  actual  quality  of  drugs  provided  by  different  
providers  in Nigeria  and  in  many  sub-Saharan  African  countries.  Such information is 
important  for  improving  malaria  treatment  that  will  help  in  the  development  and 
implementation of actions designed to improve the quality of treatment. A study conducted in 
South-East Nigeria found that there was a high prevalence of poor quality drugs (Onwujekwe 
et al., 2009). Such findings provide areas for public intervention to improve the quality of 
malaria treatment services and to forestall resistance.
The Merozoite Surface Protein1 (MSP-1) and Merozoite Surface Protein2 (MSP-2) are highly 
polymorphic markers and the large allelic polymorphism has been reported in the block 2 of 
the  msp-1  gene  and  the  central  repetitive  domain  (block3)  of  the  msp-2  gene.  Families 
differing in nucleotide sequences and in number of repetitive sequences (length variation) 
were used for genotyping purposes. This study evaluates the extent of genetic diversity in the 
field isolates of  P. falciparum  obtained from Ogun State in South Western Nigeria.   The 
population structure of  the isolates analyzed with the polymorphic markers  MSP-1, MSP-2, 
and Glutamate Rich Protein (GLURP) in this study showed extensive diversity in parasite 
populations in the four zones in Ogun State, South Western Nigeria. The MSP-1, MSP-2, and 
GLURP markers showed 8, 6, and 5 allelic families, respectively. This diversity of the  P. 
falciparum  population in South Western Nigeria is reflected in the complexity of parasite 
populations in the samples. A catalog of genetically distinct parasite populations co-infecting 
those  infected  with  malaria,  based  on  PCR amplification  of  these  markers,  showed  that 
multiplicity of infection was common. Multiclonality of infections has been shown to be a 
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common feature in  most malaria-endemic areas  (Happi  et  al.,  2004;  Ntoumi  et  al.,  1995; 
Magesa et al., 2001; Nzila et al., 2006). Epidemiologic data from some study sites in Africa 
suggest that the multiplicity of P. falciparum infection may be directly related to the intensity 
of transmission (Arnot, 1998; Babiker  et al., 1997). This multiplicity of infections may also 
have important implications for the epidemiology of drug-resistant P. falciparum malaria and 
the outcome of treatment in patients. The initial presence of several parasite populations with 
different drug response profiles would result in elimination of drug sensitive populations and 
selection  of resistant  parasites.  The findings  in  this  study are in  agreement  with those of 
previous studies involving asymptomatic carriers and symptomatic patients in holoendemic 
areas, both in the complexity of population structure and multiplicity of parasites in human 
hosts (Ntoumi et al., 1995; Snounou et al., 1999). All the MSP 1, MSP2 and Glurp families 
were represented in each of the four zones in Ogun state where samples were collected.
In  considering  possible  strategies  for  the  reduction  of  the  burden  of  antimalarial  drug 
resistance, it is useful to differentiate between the current burden of drug resistance and the 
potential  burden in the future resulting from the continued emergence and spread of drug 
resistance.  The  factors  that  are  likely  to  contribute  to  the  development  of  antimalarial 
resistance were studied through administration of questionnaire to people who live in the four 
zones of Ogun State, South Western Nigeria. 33% of respondents do have malaria at least 
once in a month and 32.1 would have malaria at least once in three months respectively. This 
means about 80.3% will have malaria at least once in a year. It was also found in this study 
that the rate of exposure to antimalarial drugs including the artemisinins is very high. 40.7% 
of  the  sample  population  use  quinolines  as  prophylaxis  while  more  than  33%  use 
sulphonamides and about 3.2% use artemisinins as prophylaxis. As long as drugs are used, the 
chance of resistance developing to those drugs is present (Plowe, 2003). It has been observed 
that  the  development  of  resistance  to  antimalarial  drugs  in  South-East  Asia  has  been far 
quicker than the estimated 12 to 17 years it takes to develop and market a new antimalarial 
compound (Ridley, 1997). 
Affordability is an essential consideration for any strategy to control drug-resistant malaria, 
especially in Africa (Foster and Phillips 1998; Goodman et al.,  1999). In the current study, 
about 25% of the sample population stops the use of drugs because of price or when they 
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finish the one they could afford. The future, especially in Africa, will also be defined by how 
well the central tenets of malaria control can be reconciled with the central tenets of control of 
drug resistance.  One of the cornerstones of the current approach to malaria  control  is  the 
provision of prompt, effective malaria treatment.  In much of Africa, easy access to public 
sector health care is limited and when it is accessible, health care staff are often inadequately 
trained, insufficiently supplied and supported, ineffectively supervised and poorly motivated 
(Goodman et al., 2000). Central to achieving a reduction in both current and future burdens is 
an  improvement  in  drug usage  by  patients  and  providers  so  that  good  quality  drugs  are 
available and taken at the correct dose and for a sufficient length of time to affect a radical 
cure and reduce the likelihood that partially resistant parasites will survive. Improving drug 
use is most effective where the parasite is still  sensitive to the drug. Where resistance has 
rendered  the  drug  ineffective,  the  current  burden  of  resistance  can  only  be  reduced  by 
replacing the failing drug regimen with one that is effective. The difficulty lies in deciding 
which drug regimen to switch to, since the choice of drug or drug combination will determine 
the  subsequent  development  of  drug resistance.  Reducing the  future  burden of  resistance 
requires that effective antimalarial drugs continue to be available in the future and requires the 
continuous search for and development of potential new antimalarial drugs.
However, the complete drug development process can take 10−15 years, making it imperative 
that the currently available drugs are deployed in a way most likely to maximize their lifespan 
by decreasing the likelihood that resistance will develop. The key strategy put forward to do 
this  is  to  use  available  drugs  in  combination  to  prevent  the  emergence  and  spread  of 
resistance. Once a drug-resistant mutant has arisen, preventing spread of resistance is difficult. 
Spread  is  facilitated  by  the  exposure  of  malarial  parasites  to  sub-therapeutic  levels  of 
antimalarial drugs, that kill sensitive parasites but allows parasites with a resistance mutation 
to  survive and reproduce.  Ensuring that  drugs are  taken in  at  a  sufficient  dose and for a 
sufficient duration reduces this risk. Drug pressure is higher where a drug with a long half-life 
is taken because the drug remains in the patient’s blood at low levels for weeks, exposing any 
newly introduced malarial parasites to sub-therapeutic levels (Bloland, 2001).
This  is  particularly  likely  to  occur  in  high  transmission  areas  where  people  are  not  only 
infected more frequently, but also take antimalarial drugs frequently whether or not they are 
having malaria. Theoretically,this form of drug pressure can be reduced by using drugs with a 
101
shorter half-life and by restricting the use of the first line drug to patients with confirmed 
malaria: i.e., only treating those with a definitive diagnosis.
CONCLUSION
This study has established the incidence of falciparum malaria in Ogun State, Southwestern 
Nigeria. Moreover, a baseline for both genetic polymorphisms and drug sensitivity profiles of 
P. falciparum isolated from Ogun State Nigeria has been established. This data should serve 
as a baseline for future studies to monitor the changes in antimalarial drug resistance in this 
part of the country. To prevent resistance to antimalarial drugs, a high degree of vigilance is 
required;  the  level  of  antimalarial  drug  sensitivity  of  P.  falciparum  should  be  closely 
monitored while compliance to antimalarial drug use should be encouraged.
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CONTRIBUTIONS TO KNOWLEDGE
This research work has contributed to knowledge in the following ways.
1. The  incidence  of  malaria  (Plasmodium infection)  in  Ogun  state,  South  Western 
Nigeria  has  been  established.  This  would  help  in  planning  prevention/control 
operations, resource allocation, and upgrading medical facilities in hospitals to treat severe 
and complicated cases.
2. The resistance pattern of Plasmodium falciparum isolates from Ogun State to existing 
antimalarial  drugs  established  in  this  study  would  tailor  drug  choices  specific  to 
geographic regions.
3. The molecular diversity of P. falciparum strains in Ogun State, Southwestern Nigeria 
has  been established.  This  Knowledge would help to  type and characterize  the  P. 
falciparum strains in Nigeria and compare their diversity with the rest of the world.
4. Results from molecular studies on the drug resistance genes of P. falciparum obtained 
in this study would provide advance information on the emergence of drug resistance 
in the field. This knowledge should facilitate the ability to begin to anticipate genomic 
responses to drugs yet unseen by the parasite.
5. Some of the factors which contribute to the development of resistance of Plasmodium 
to antimalarial drugs have been established. This should lead to the development of 
strategies and policies to control the use of existing antimalarial drugs and forestall 
resistance to new drugs. 
6. Antimalarial  efficacy of some local herbs used as herbal drugs has been established. 
This is expected to lead to the discovery of novel antimalarial drug of local origin. 
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RECOMMENDATION
There is an urgent need to find and develop alternative drugs against multidrug-resistant  P. 
falciparum.  One group of alternative antimalarial  drugs comprises artemisinin (qinghaosu) 
and  its  derivatives.  Artemisinin  is  a  traditional  Chinese  medicinal  herb  derived  from 
Artemisia annua.  Newer antimalarial drugs and approaches to overcome parasite resistance 
are  needed  to  deal  with  the  expanding  problem  of  drug  resistance  which  continues  to 
challenge  malaria  control  efforts  based on early diagnosis  and treatments.  Only a  limited 
number  of  antimalarial  drugs  are  currently  at  an advanced stage  of  clinical  development. 
There must therefore be a renewed interest in plant products. An attractive option for poor and 
developing countries is the exploitation of the possible therapeutic effects of their local herbs.
Efforts must be made to reduce drug pressure which can lead to the selection of drug-resistant 
parasites. 
Since there was positive correlation between artesunate and mefloquine; artesunate quinine, 
drugs containing these combinations should be recommended for Ogun State, the study area.
There  is  little  existing  knowledge  about  actual  quality  of  drugs  provided  by  different  
providers  in Nigeria  and  in  many  sub-Saharan  African  countries.  Such information is 
important  for  improving malaria  treatment  that  will  help  in  reducing  the  development  of 
resistance to the antimalarial drugs in use. 
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APPENDICES
APPENDIX I
Preparation of Culture Medium (Stock)
One packet of RPMI which contains 25mM of HEPES buffer was dissolved in 960ml of triple 
distilled water. 2gm of glucose was added and dissolved. 40µg/ml of Gentamycin Sulphate 
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was added to  prevent  contamination.  The solution  was sterilized  by passing  it  through a 
Millipore filter of 0.22µm porousity and was stored at 40C as 96ml aliquots in glass media 
bottles.
 Preparation of 5% Sodium Bicarbonate 
5gm of Sodium bicarbonate was dissolved in 100ml of double distilled water. The solution 
was filtered through a Millipore filter of 0.22µm porosity and stored at 40C
 Preparation of Incomplete Culture Medium (washing medium)
4.0 ml of 5% Sodium Bicarbonate was added to 96ml of stock RPMI 1640. This was prepared 
fresh when needed.
3.8.5 Preparation of Complete Culture Medium
To prepare 100ml of the medium, 90ml of RPMI 1640 solution containing 5% NaHCO3 was 
mixed with 10ml of human serum. The medium was then stored at 4oC. Complete culture 
medium  is  a  3:1  mix  (vol/vol)  of  RPMI  1640  medium  containing  4-  (2-hydroxyethyl) 
-piperazine-ethanesulfonic  acid  i.e.  HEPES (25 mM),  NaHCO3 (25 mM),  and Waymouth 
medium  (Flow  Laboratories,  Irvine,  United  Kingdom)  supplemented  with  12%  (vol/vol) 
human type AB Rhesus negative serum and hypoxanthine (10 μg/liter).
Preparation of Giemsa Stain
To prepare 400ml of Giemsa stain, 3g of Giemsa powder was dissolved in 200ml of glycerol. 
200ml of methanol was added. The solution was be incubated in water bath for two hours 
with gradual shaking at five minutes interval (Cheesebrough, 2001).
APPENDIX II
Questionnaire
A survey of the predisposing factors to the development of antimalarial 
drug resistance in Plasmodium falciparum in South Western Nigeria
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1. Residential area:   Town/City/Village …………………..
2. Sex M        F 
3. Age 18 – 25    26 – 35      36 – 45    45 and above      
4. Educational Background:
Non formal    Quranic    Primary   Secondary               Post 
Secondary 
5. Main Occupation:
Teaching    Trading     Student      Artisan     Housewife    
Farming       Civil Servant      Others     Specify
History of malaria disease/infection and management: 
6. How often do you have malaria – 
Once in a month      once in three months       
Once a year      Twice a year      Others     Specify
8.  Where  do  you  seek  Medical  advice  when  you  experience  symptoms  of 
malaria?
From: Doctors/Hospitals     Nurse/midwife     Pharmacists     Chemists       Self 
medication    others  List them
9. Thick appropriately, any antimalarial drug that you have used before 
     Chloroquine      Amodiaquine        Quinine           Fansider      Maloxine 
Amalar    Malamox    Halfan      Lornart     Alaxin       Artesunate   
Artemether     arteplus      others     specify 
10. Which of the above drugs do you take frequently       (mention)
……………………………… …………………………………….. 
…………………………
11. Do you take these drugs based on doctors’ prescription?  
Yes        No 
12. If yes do you take the full regimen as directed by the doctor?
 Yes       No. 
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13. When do you stop medication?
a) When I feel okay
b) When I complete dosage
c) Anytime I like
d) When I finish what my money can buy
e) Others (specify)
14. What factors influence you to stop the medication?
a) Price of drugs
b) Dislike for drugs
c) Fear of overdose once the fever is down
d) When I feel cured
e) Personal/religious beliefs
f) Others (specify)
15. Do you take all drugs prescribed by the doctor?
Yes      No     All drugs except the vitamins 
Just the ones I feel are important 
16. Do you belief there is a need for Doctors’ prescription?  
Yes      No   
17. Do you take antibiotics in combination with above antimalarial drugs? Yes   
No 
18. Which antibiotics do you take in combination with antimalarial drugs? 
(Mention)………………………
19. Do you follow doctors’ prescription strictly?    Yes        No 
20. Do you take any local herbal preparation to cure malaria?  Yes     No 
Mention the local name of the herb………………..
21. Do you get a medical Laboratory diagnosis before administration of    drugs?
Yes        No        Sometimes 
22. Do you take antimalarial drugs as prophylaxis/preventive against malaria? 
Yes     No  If yes, mention the drugs you take to prevent 
malaria…………………
23. How effective is the antimalarial drug you commonly use in case of malaria
Highly ineffective 1 2 3 4 5 extremely effective (circle as appropriate)
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24. Which of these do you consider most effective for the cure of malaria?
 Local herbal preparation    Doctors’ prescribed drugs
 Traditional healers              others (specify)
25. Which method do you use to prevent mosquito bite/transmission of malaria 
infection?
 Window/door nets                Insecticide treated bed nets 
 Insecticide spray (specify)     Mosquito repellent creams     mosquito 
coils     others (specify)
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ASSENT FORM
 Title of study:                                               
IN-VITRO AND MOLECULAR STUDIES ON THE RESISTANCE OF P. 
falciparum TO ANTIMALARIAL DRUGS IN OGUN STATE, SOUTHWESTERN 
NIGERIA
  
Date
Dear participant,
This is to seek your assent despite the explanation given to you and your parent/guardian on 
the above project.  You are free to  decline to participate  even if  your parent/guardian has 
agreed on your behalf. If you agree that your blood be taken for the tests required in the study 
Please signify by nodding your head.
HEAD NODDED……………………………………..
HEAD NOT NODDED…………………………………….
Witness;
Signature……………………………………………….
Thank you,
Olasehinde, Grace I.
Principal investigator 
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IN-VITRO AND MOLECULAR STUDIES ON THE RESISTANCE OF P. 
falciparum TO ANTIMALARIAL DRUGS IN OGUN STATE, SOUTHWESTERN 
NIGERIA
   Date
Dear participant,
You  are  invited  to  participate  in  the  above  research  study,  which  has  been  designed  to 
determine the incidence of malaria,  the resistance patterns of the malaria  parasite and the 
possible factors that may contribute to the development of resistance to antimalarial drugs by 
the parasites in South Western Nigeria
You will  be  subjected  to  malaria  screening  test  which  requires  2mls  of  blood  from you 
through venepuncure; this same blood will be processed to get the DNA there from. The DNA 
will  be  screened  for  novel  resistance  genes  using  molecular  methods.  You  will  also  be 
required to complete a questionnaire and it will take you about 10minutes.
The information generated from this survey will  be of direct benefit  to you as it  aims at 
prevent incessant use of drugs, and will probably contribute to general knowledge on how to 
proffer public health intervention that will help control malaria in this part of the country.
Meanwhile, the study will not disclose any confidential information pertaining to you but the 
information generated can be used for public health intervention as regards the disease in 
south western Nigeria.
Your decision to participate is voluntary. You are free to decline to participate in this study, or 
to withdraw your information, at any time.
Before  you  complete  the  questionnaire  or  decide  to  participate  in  this  study,  please  ask 
questions  on any aspect  of the study that  is  not clear  to you. If  you have any additional 
questions later, you can contact Olasehinde Grace on 08055439005.
Address :
Mrs. Grace Olasehinde
Department of Biological Sciences
College of Science and Technology
Covenant University
P.M.B. 1023,Ota
Ogun State, Nigeria
            e-mail; golasehinde@yahoo.com
………………………………..                                                       ……………………..
       Signature of participant    Date 
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Fig 4.1. Parasitaemia Rate by Age
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Fig 4.2. Percentage Incidence of P. falciparum Infection in Ogun State
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Bednets, ITN (18.0%)
Insecticides (24.0%)
Mosquito repellent cream
(2.7%)
Window/door nets
(42.3%)
None (13%)
Mosquito – bite preventive methods employed by respondents.
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